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Development of new polymer structures for local drug delivery to the brain is an exciting 
research area. The main aim of this study is to develop biocompatible controlled drug 
delivery systems, using biodegradable or conducting polymers, for the treatment of central 
nervous system disorders such as epilepsy.  
 
Epilepsy affects 1% of the global population and is drug-resistant in more than 30% of cases. 
The reasons for this are still not well understood. However, there is a significant body of 
evidence pointing to the blood-brain barrier. Resective surgery can provide an alternative 
method of epilepsy control; however, this treatment option is not suitable for most epilepsy 
sufferers. To improve the therapeutic efficacy of epilepsy medication, a promising approach 
is to deliver anti-epilepsy drugs directly to affected brain areas using appropriately designed 
implantable local drug delivery systems, therefore avoiding the blood-brain barrier. The drug 
delivery systems must meet some criteria, including high drug encapsulation efficiency, 
biodegradability, neuro-cytocompatibility and predictability of drug release profiles. Here, 
Chapter 3 investigates the development of fibre- and sphere-based microcapsules that exhibit 
controllable and uniform morphologies and drug release profiles as predicted by 
mathematical modelling. Importantly, both forms of fabricated microcapsules are compatible 
with human brain-derived neural stem cells and their differentiation to neurons and 





After that, to develop effective local delivery systems with longer release periods and more 
diverse release profiles, preparation of a variety of core-shell microcapsules via novel core-
shell electrojetting, where a more hydrophobic polymer shell acts as a physical barrier to 
control the rate of drug release from the drug-loaded polymeric core, was considered in 
Chapter 4. The resulting microcapsules demonstrated high drug encapsulation efficiency, 
narrow size distribution and uniform morphology. Moreover, the release rate of drugs can be 
modulated by controlling the morphologies of the core-shell microcapsules. 
 
Combination therapy involving more than one medication has shown promise in the 
treatment of a number of diseases. A key challenge is to concurrently ensure effective doses 
for each medication. Therefore, there is an urgent need for developing dual or multi-drug 
delivery systems to attain sustained and predictable release profiles for individual drugs. 
Chapter 5 presents a simple and versatile approach to developing dual drug delivery systems. 
Both electrospinning and electrospraying were employed to fabricate composite membranes 
that were composed of microfibrous matrices interspersed with microspheres. Two different 
composite membranes were fabricated including PLA phenytoin fibre/ PLGA lacosamide 
sphere composite membranes and PLA lacosamide fibre/ PLGA dexamethasone sphere 
composite membranes, respectively.  The resultant composite membranes exhibited 
favourable thermal and mechanical properties. In contrast to loading dual or multiple drugs 
into the same micro- or nano- structure, these dual microstructural composite membranes 
show not only controllable dosage but also different release rates for each drug 





On-demand drug delivery is becoming feasible through the application of appropriate stimuli-
responsive materials. In addition to the above passive drug delivery systems, we have also 
developed 3D electrically responsive system for programmed drug delivery in Chapter 6. 3D 
printed (selective laser melting) interdigitated Ti6Al4V electrodes were used for 
electrodeposition of conductive polymer coatings (polypyrrole) doped with an anti-epilepsy 
prodrug, fosphenytoin. We have shown that drug release from the 3D conductive electrodes 
is precisely controlled by biphasic electrical stimulation. Moreover, dual drug delivery is 
achieved by further coating of the 3D electrodes with dexamethasone-loaded biodegradable 
microspheres. The interdigitated electrodes can be served as multi-function drug delivery 
systems. These 3D printed electrodes represent a novel electrically on-demand drug delivery 
system for treatment of central nervous system diseases including epilepsy. 
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AEDs; Anti-epilepsy drugs 
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Mt; Molar weight at any time 
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1.1 Drug delivery general introduction  
Advanced systems for drug delivery have attracted tremendous interest recently, in particular 
in the field of developing technologies concerning drug formulation, route of administration, 
site targeting, metabolism, and toxicity [1-12]. These technologies aim to deliver 
pharmaceutical agents to the site of action in order to maximize the therapeutic effect, 
minimize side effects, and enhance patient compliance. Unfortunately, there are two types of 
barriers to these delivery processes; (i) the complexity of the paths to reach the target disease 
site, and  (ii) the limitation of tools to control the delivery behaviour [6, 13]. When the 
administered drug (free without a carrier) arrives into the human bloodstream, it will undergo 
various metabolic processes, such as renal clearance and distribution in non-target tissues 
[14]. Usually, these metabolic processes reduce the drug concentration and therapeutic effect 
at target tissues and increase the toxic side effects. However, due to the development of 
materials science and pharmaceutics, a wide range of carriers with multiple functions, diverse 
architectures, and special surface properties have been investigated [11, 15, 16].  
 
1.1.1 Oral drug delivery 
The most favourable drug administration is oral dosage, near 80% of the worldwide market 
[17]. It is patient friendly, non-painful, and convenient for self-medication. Compared to the 
administration via injection (subcutaneous, intramuscular, and intravenous delivery, etc.), 
oral delivery reduces the risk of disease transmission, cost, while increasing patient 
compliance. However, with the development of new therapeutics, more and more 
biotechnology-based drugs such as peptides, proteins, and other macromolecular drugs have 
been very effective in treating various diseases. Because of their structures, effective 





Figure 1.1 The possible obstacles for oral delivery of biological therapeutics. Reproduced 
from reference [20].  
 
Due to gastrointestinal barriers (Figure 1.1), these biological therapeutics have poor oral 
bioavailability and are rarely used for direct oral administration [20, 21]. Therefore, it is 
necessary to design effective drug delivery systems in order to improve their bioavailability. 
Tremendous attempts have been made to overcome the challenges presented by the 
gastrointestinal barriers for oral delivery of therapeutic peptides and proteins, among which 
novel nanocarriers have shown their potential for improved oral administration [20]. The 
nanocarriers include nanoemulsions, dendrimers, micelles, liposomes, solid lipid 














nanocarriers has their own limitations, and much work still needs to be done in order to gain 
wide clinical acceptance [23].  
 
1.1.2 Transdermal drug delivery 
Transdermal drug delivery has attracted tremendous interest and provides an attractive 
alternative to oral delivery and hypodermic injections [3, 24]. Besides being non-invasive and 
easily self-administered, in some cases, it can improve patient compliance and provide a 
release for long periods of time. Compared with oral administration, transdermal delivery has 
a particular advantage which can avoid the first-pass effect of the liver that can prematurely 
metabolize drugs [25]. Transdermal delivery also has advantages compared with hypodermic 
injection, which is painful and generates dangerous medical waste. Additionally, transdermal 
delivery systems are generally inexpensive compared to hypodermic injections, and would 
be only slightly more expensive than a tablet.  
 
The first systemic transdermal delivery was approved by the Food and Drug Administration 
(FDA) in 1979 and used for motion sickness treatment. Until now, more than one billion 
transdermal patches are produced every year. However, only a limited number of drugs are 
amenable to administration by transdermal delivery, which is one of the greatest challenges 
for this administration method [24]. This limitation is ascribed to the inherent skin barrier 
function. Skin is the largest organ of the human body with a very low permeability for 
foreign molecules. As shown in Figure 1.2, the outmost layer is the stratum corneum. There 
are tremendous lipids organized in bilayer structures between corneocytes which provide a 
primary barrier to drug molecular penetration. The middle layer is viable epidermis. It 
5 
 
possesses the function for stratum corneum continuous renewing. The inner fibrous layer is 
the dermis, which provides the mechanical support for the skin [26].  
 
 
Figure 1.2 Histological structure of human skin. Reproduced from reference [24]. 
 
Transdermal delivery systems can be divided into three generations:  
 1st generation consists mostly of the patches produced today. The therapeutics in these 
patches can cross the skin but with little or no enhancement in penetration rate. For 









 2nd generation of transdermal delivery systems have been developed for delivery of 
small molecules with enhanced skin permeability and driving forces. 
 3rd generation of transdermal delivery systems enable transdermal delivery of not only 
small molecule drugs, but also biological macromolecules, such as virus-based and 
other vaccines et al. This generation enables stronger disruption of the stratum 
corneum barrier, and is thereby a most effective transdermal delivery system [28]. 
However, the third generation of transdermal delivery systems are still at an early 
developmental stage.   
 
1.1.3 Local drug delivery 
In systemic drug delivery, the drug enters into the blood circulation system where the 
concentration can quickly drop below an effective level. In addition, too much drug 
distributes to non-target tissues with only a small portion of the drug reaching the target site. 
To increase the dosage to the target tissues in these situations, re-administration is required,  
which unfortunately leads to an increased risk of overdose and the possibility of serious side 
effects [29]. 
 
Local drug delivery, also known as regional drug delivery, is an approach which has been 
developed to improve the selectivity of therapeutic reagents for target tissues. Compared with 
the systemic drug delivery routes, local delivery could significantly increase the drug 
concentrations at the disease site, thereby reducing drug loading dosage required since it is 
effective at avoiding the anatomic or physiological barriers, which lead to rapid drug 
elimination during the systemic circulation or in non-target tissue [30]. As shown in Figure 
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1.3, one of a most typical example of local drug delivery study is implanting these delivery 
systems next to tumours for continuously long period release [31]. 
 
 
Figure 1.3 Local drug delivery strategies for cancer treatment, including a) wafers in the 
brain, b) film in the lung, c) rod in the liver, d) gel in the intestine or stomach, d) 
nanoparticles in the ootheca. Reproduced from reference [31]. 
 
1.1.4 Targeted drug delivery 
The concept of targeted drug delivery was first proposed by Ehrlich at the beginning of the 
last century [32]. Until recent decades, targeted drug delivery has been approaching the 
forefront of biomedical research [33-38]. By combination of therapeutic reagents with a 
smart carrier, targeted drug delivery systems can be selectively accumulated in targeted cell, 













reduce the frequency of the dosage taken, fluctuation in circulating drug levels, and side 
effects associated with drug toxicity in non-targeted areas [34]. 
 
1.1.4.1 Kinds of targeting strategies 
There are two kinds of strategies used for the targeted delivery of polymer encapsulated drug 
to cancerous tissue: passive targeting and active targeting [39]. Passive targeting relies on the 
Enhanced Permeation and Retention (EPR) effect. As a result, the concentration of the drug 
delivery systems in tumour tissue can be much higher than those in normal tissue (Figure 
1.4).  
 
Figure 1.4 Schematic illustrations of passive targeting delivery compared with free drugs 
without a carrier. Reproduced from reference [40]. 
Normal tissue pH 7.4






However, due to the presence of various biological barriers in the human body, the actual 
concentration of a drug at the tumour site can be low, yielding a low therapeutic efficacy 
[41]. Different from passive targeting, active targeting conjugates target molecules on the 
surface of polymer encapsulated drug particle (Figure 1.5). It can recognize and bind to 
specific ligands on the cancer cells [39]. This approach significantly increases the drug 
concentration in the tumour site by both local and systemic administration. 
 
 
Figure 1.5 Schematic illustration of active targeting delivery, using folate modified 














1.1.4.2 Application in cancer therapy 
Cancer therapy is one of the most important applications of targeted drug delivery [37]. 
Cancer is a group of diseases involving abnormal cell growth, which causes nearly 14.6% of 
human deaths each year [42]. It was considered incurable, but most patients diagnosed and 
treated at an early stage will survive today. There are over 100 known cancers that affect 
humans, for most of them; chemotherapy has become an integral component of cancer 
treatment. However, chemotherapeutic agents typically have poor specificity in reaching 
tumour tissue and are often restricted by dose-limiting toxicity. Development of proper target 
polymer encapsulation drug delivery can provide a more efficient and less harmful solution to 
overcome the limitations.  
 
1.1.4.3 Application in brain-related diseases 
Another interesting and important application of targeted drug delivery is the development of 
nanoparticles for delivery of drugs to brain-related diseases [43-45]. Compared with delivery 
targeting to other organs, drug delivery to the brain is more challenging; since drugs have to 
cross the blood brain barrier (BBB) before reaching the targets. The BBB serves to restrict 
the movement of substances between the CNS and the blood circulation. It is formed 
primarily by endothelial cells which form complex, tight junctions (Figure 1.6) with 
substantial transendothelial electrical resistance, creating a physical barrier that severely 





Figure 1.6 The blood-brain barrier (BBB) is mainly composed of vascular endothelial cells, 
highly connected by adherens and tight junctions, and a sparse layer of pericytes. Reproduced 
from reference [45]. 
 
In order to deliver the drugs to the brain, tremendous efforts have been made to develop 
nanoparticle-based targeted drug delivery for systemic delivery of therapeutic reagent [45-
47]. Usually, the nanoparticle-based targeted drug delivery surface is modified to specifically 
recognize and bind exclusively to the surface of diseased cells [47]. The nanoparticle-based 
targeted drug delivery systems include polymer nanoparticles and micelles, liposomes, 









been designed to improve delivery efficiency, drug nanomedicine, and to reduce off-target 
effects of drug payload.  
 
1.2 Polymer for drug delivery 
Spurred by progress in materials science and fabrication techniques, a wide range of materials 
have been applied in drug delivery as carriers. Among them, polymers are one of the most 
commonly used materials [48-53]. Due to their diversity in chemistry, architecture, and 
dimension, polymer materials can meet the increasing requirements of developing new drug 
delivery systems [54]. Most of the well-developed polymeric carriers are compatible with the 
drug to form stable delivery systems during synthesis, storage, and administration process.  
 
The first investigation of controlled release from polymers was conducted by Folkman and 
Long in 1964 using silicone rubber [55]. Later, in the 1970s, the biodegradable polymers 
were applied as drug delivery materials [56]. At that time, the concept of “drug delivery” is 
limited to achieving sustained long period of the releasing time. Today, after nearly half a 
century of development drug delivery systems possess more smart release behaviours and 
diversity in functions. During this time, a large number of polymers including different kinds 
of natural, semi-natural, and synthetic polymers have been investigated. And several 
polymer-based drug delivery systems have been “Regulatory Approved,” reaching the market 
[57]. There are several important characteristics of polymeric carriers such as molecular 
weight and its distribution, shape (architecture), size, and surface properties including 
hydrophobicity, hydrophilicity, and charge density. Considerations of these important 
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characteristics, the biodegradable polymer and conducting polymer have received tremendous 
interest in drug delivery research. 
 
1.2.1 Biodegradable polymer 
The polymers used for therapeutic applications can be divided into two main classes: 
biostable polymers and biodegradable polymers [58]. Biostable polymers have been used for 
a long time both for permanently and temporarily in drug delivery. However, soon after they 
emerged, biodegradable polymers have received great interest for temporary therapeutic 
applications [59-63].  
 
Prior to the Second International Scientific Workshop on Biodegradable Polymers and 
Plastics at Montpellier, France, there were many definitions of the term “biodegradable 
polymers.” It was at this workshop that a unified definition of the degradable polymer was 
established as “a polymer in which the degradation is mediated at least partially by a 
biological system.” According to resources, the biodegradable polymers can be either natural 
or synthetic. No matter natural or synthetic, the desirable characteristics of polymer carriers 
are biocompatible with the human body, nontoxic, and biodegradable [64-66]. Application of 
natural biodegradable polymers for drug delivery is still attracting research since these 
polymers are naturally available, relatively inexpensive. However, for the selection of a 
biodegradable polymer carrier, there is a criterion that the mechanical properties and the 
degradable rate should match to the needs of the clinical application [67]. Therefore, the 




1.2.1.1 Biodegradable polyesters 
Table 1.1  Examples of commonly used biodegradable aliphatic polyesters and their thermal, 





































Amorphous 50-55 2.0 5-6 
 
The most widely investigated synthetic biodegradable polymers used in biomedicine for drug 
delivery are aliphatic polyesters such as poly(glycolic acid) (PGA), poly(lactic acid), 
poly(lactic-co-glycolic acid) (PLGA) and poly(ε-caprolactone) (PCL) respectively; as shown 





Figure 1.7 Most commonly used biodegradable polyesters. a) L- and DL-PLA, b) PGA, c) 
PLGA, d) PCL. 
 
These aliphatic polyesters are derived from the lactic and glycolic acids monomers. 
Compared to some natural biodegradable polymers (such as collagen, gelatin, chitosan, and 
alginate), these synthetic biodegradable polymers are commercially available in different 
compositions and molecular weights, and which allow control of degradation rate of the 
polymers. Those early investigations demonstrated the well biocompatible, nontoxic, and 






1.2.1.2 Erosion and drug release mechanisms 
 
 
Figure 1.8 The schematic illustration of erosion mechanisms: surface erosion (left) and bulk 
erosion (right). Reproduced from reference [71]. 
The aforesaid polyesters are generally prepared by ring-opening polymerization of the cyclic 
esters. The degradation describes the process of polymer chain cleavage, leading to molecular 
weight loss. And the degradation results in the subsequent erosion of the polymer. For the 
biodegradable polymers, there are two kinds of erosion mechanisms: bulk erosion and surface 
erosion [71]. Bulk erosion is also known as homogeneous erosion; surface erosion is also 
known as heterogeneous erosion (as shown in Figure 1.8). Due to water penetration into the 




Surface erosion Bulk erosion
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cross-section. In contrast, for surface erosion biodegradable polymer, the degradation is faster 
than the penetration of water into the bulk. However, for most biodegradable polymers, both 
of these two mechanisms would occur with the erosion mechanisms having consequences on 
the drug release mechanisms.  
 
The drug release mechanisms from these biodegradable polymer matrices can be divided into 
three kinds: (i) diffusion controlled, (ii) swelling controlled, and (iii) erosion controlled 
(Figure 1.9). Degradation of the polyesters starts with the hydrolytic breakage of the ester 
bonds. It occurs randomly via hydrolytic ester cleavage when water penetration into the 
polymers leads to the subsequent erosion. Many parameters affect the degradation rate; 
including molecular weight, polydispersity and crystallinity, polymer composition, and all 
these factors can be used to control drug release [72]. For example, the copolymer PLGA, 
which is a copolymer consisting of lactic acid and glycolic acid, the rate of degradation 
increases with the ratio of glycolic acid to lactic acid. As an exception to this rule, when the 
ratio of lactic acid and glycolic acid is 50/50, the rate of degradation is the fastest, 





Figure 1.9 Mechanism of drug release from degradable polymers. Reproduced from 
reference [74]. 
 
1.2.1.3 Application in drug delivery 
Recently, a wealth of studies has been conducted using PLGA, PLA as carriers for drug 
delivery. In order to efficiently transport to the central nervous system through the blood-
brain barrier, Fornaguera et al. used nano-emulsion with a low-energy method to fabricate 
loperamide loaded PLGA nanoparticles (as shown in Figure 1.10) [75]. Firstly, non-loaded 
polymeric O/W (Oil phase/Water phase) nanoemulsion was prepared. Then, the emulsions 
with 90 wt% of aqueous phase content and 70/30 O/W ratio was selected as a compromise 












reformulated containing 0.1 wt% drug in the oil phase and the droplet size around 100 nm. 
Then, the drug-loaded PLGA nanoparticles were finally obtained by solvent evaporation. 
This is a methodology which can be easily applied to the scalable production of nanoparticles 
of biodegradable polymers (PLGA). 
 
 
Figure 1.10 Schematic illustration of the fabrication and function of the loperamide loaded 
PLGA nanoparticles. Reproduced from reference [75]. 
 
Ye et al. developed biodegradable polymeric vesicles as a nanocarrier system both for 
multimodal bioimaging and anticancer drug delivery [76]. They synthesized PLGA-SPION-
Mn:ZnS vesicles as a multifunctional drug delivery system. It used the biodegradable 
polymer as a shell containing multiple imaging agents and anti-cancer drug (Figure 1.11). 
This drug delivery system showed enhanced imaging contrast, improved cell uptake, and 
enhanced fluorescence visualization. It also exhibited both high entrapment efficiency for the 
lipophilic drug busulfan and sustained drug release. The in vivo results confirmed the 
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biodistribution to different tissues. Wan et al. developed PLGA microparticles by using the 
spray-drying method. They used different molecular weight PLGA and different solvent 
mixtures, which resulted in different drug diffusion rates during the process of microparticle 
formation and the drug release profiles were dependent on the solvent composition.  
 
 
Figure 1.11 Schematic illustration of the composition of PLGA composite nanoparticles and 
their applications. Cited from reference [76]. 
 
Combining different biodegradable polymers or other polymers together to form a composite 
carrier is also an attractive research area. PLGA nanoparticle was coated with a layer of 
polydopamine. Then a layer of poly(ethylene glycol) was formed and the drug loading 
content achieved a 3.8-fold increase [77]. Covalent surface modified PLGA microparticle 
demonstrated enhanced durable binding on targeted cells and ultra-high cytostatic efficacy 
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[78]. Chitosan was also used to modify PLGA nanoparticles, and it showed a positive charge 
surface and affected the drug release profile [79]. Other interesting work is that of the 
fabrication of a hybrid dendrimer hydrogel/PLGA nanoparticle which can enhance drug 
bioavailability, reduce dosing frequency, and substantially enhance sustaining drug activity 
[80]. 
 
1.2.2 Conducting polymers 
Conducting polymers can be categorized as intrinsic conducting polymers or composite 
conducting polymers [81]. Here the focus is on intrinsic conducting polymers. Conductive 
polymers are organic polymers with metallic electrical properties [82]. The first conducting 
polymer, polyacetylene (PAc) was discovered in 1977 at Tokyo Institute of Technology by 
Shirakawa et al. [83]. Until now, after several decades investigation and development, a 
series of conducting polymers have found use in a wide range of applications both in research 
and industry [84-90]. The most widely applied conducting polymers are polypyrrole (PPy) 
[91, 92], polyaniline (PANi) [93, 94], polythiophene (PT) [95], and poly(3’4-













Table 1.2  Typical conducting polymers and their structures. 















1.2.2.1 Synthesis of conducting polymer 
Conducting polymers can be synthesized by chemical or electrochemical means, and involves 
oxidative polymerization [82, 98]. Usually, the conducting polymers used for drug delivery 
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are synthesised by using electrochemical oxidation. Compared to chemical polymerization, 
the electrochemical polymerization process can be easily controlled by adjusting the amount, 
and rate of charge passed during growth. Even the morphology and electromechanical 
properties  can be controlled [99].  
 
The electrochemical oxidation in conducting polymer preparation process is usually carried 
out using two-electrode or three-electrode systems with a reference electrode, a counter 
electrode, and a working electrode [100]. The reference electrode is often silver/silver 
chloride (Ag/AgCl), the counter electrode usually is platinum, and the conducting polymer is 
deposited on the surface of the working electrode. Synthesis can be performed using either 
constant potential, constant current or cyclic voltammetry which is referred to as 





Figure 1.12 The principle of electropolymerization of polypyrrole: the monomer is pyrrole, 
A
- 
is negative drug molecule, e
-
is electronic charge. Cited from reference [101]. 
 
Many parameters affect the final conducting polymer properties. However, the key process is 
related to doping which incorporates anionic molecules into the polymer backbone [102]. 
Take polypyrrole preparation for example, where the dopant is A
- 
(inserted into polypyrrole 
backbone to alter the electrical characteristic), the pyrrole monomers would be 
electrochemically oxidized and polymerized on the surface of the working electrode. At the 




with radical-radical coupling at α positions. The neutral dimer can then be oxidised to a 
radical and later react with a monomer, dimer or oligomeric radical to grow the chain (as 
shown in Figure 1.12) [101, 103].  
 
1.2.2.2 Properties of conducting polymer 
The inherent conductivity is attributable to the uninterrupted and ordered π-conjugated 
structure of the polymer backbone (Table 1.2) [104]. The contiguous sp
2
 hybridized carbon 
centres have high mobility when the polymers are doped by oxidation, which is responsible 
for the electrical conductivity of the polymers. There is a one-dimensional electronic band 
within the conducting polymers, and the electrons within this band would become mobile 
electrons when holes are formed (empty of electron). The free electrons move along the 
polymer backbone and result in the conductivity of the polymers (Figure 1.13). The degree 
of conductivity depends on the electrons density and mobility, which can span several orders 






Figure 1.13 Schematic illustrations of the conduction process in polypyrrole. 
The mechanical properties of most conducting polymers are poor. They are brittle and easily 
destroyed. The processability of conducting polymers is also poor. Most of them are not 
soluble in common solvents, and cannot be melt processed. However, some polymers such as 
polypyrrole and poly(3’4-ethylenedioxythiophene) have good biocompatibility and have been 
widely applied in biomedical areas. Studies have shown that bioactive molecules can be 
incorporated into the conducting polymers to enhance their biocompatibility [106, 107]. 
Moreover, the cellular reactions associated with implanted devices can be modulated by 
stimulation via the conducting polymer [108]. 
 
1.2.2.3 Application in drug delivery 
In drug delivery applications, negatively charged drugs or biomolecules have been 
incorporated into conductive polymers such as Polypyrrole or PEDOT, during the process of 





Figure 1.14 The drug release from conducting polymer in response to electrical stimulation. 
 
The electrically triggered release involves a synergistic process of electrochemical 
reduction/oxidation and electrically driven movement of these charged molecules (dopant). In 
drug delivery studies, charged drugs or biomolecules could be incorporated into the PPy 
coating [109, 110]. When the PPy coating is electrochemically reduced, the doped molecules 
will be released (Figure 1.14). The release of the drug is associated with the change of the 










Many parameters affect the amount of drug released and the release rate from conducting 
polymers. As mentioned above, the conducting polymers for drug delivery applications are 
usually deposited on the electrode as a film. Therefore, the total amount of the incorporated 
drugs is related to the film thickness and density. Increasing the thickness and density will 
lead to increased drug loading. However, the available drug for releasing is not linearly 
increased with the thickness of the film. The thinner film could release a higher percentage of 
the incorporated drugs [111, 112]. Actually, the releasing amount from conducting polymer is 
a surface area dependent process, with drug releasing more efficiently from the surface than 
the bulk of the film [113]. 
 
It has been demonstrated that the media used for release studies, with variations of pH, ionic 
strength, influence the release profile from a conductive polymer [114]. However, electrical 
stimulation parameters are key determining factors, affecting both the release amount and 
release rate [115]. Potential sweeping has been used to release the drugs [116, 117]. Another 
frequently applied electrical stimulation waveform is pulsed potential which changes the 
potential instantaneously between set potentials [118, 119]. In addition, there is a clinical 
stimulation to stimulate the conducting polymers by using a biphasic, charge balanced, and 
high frequency current stimulation [120]. 
 
1.3 Technology in drug delivery 
To overcome the problems raised by present drug administration, advanced nanotechnology 
for fabricating nano- and micro-scale drug delivery systems has gained tremendous attention 
[39, 121-129]. Compared with conventional technology, nanotechnology may revolutionise 
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the rules and possibilities of drug discovery and change the landscape of pharmaceutical 
industries [121, 130-133]. By application of nanotechnology to fabricate proper drug delivery 
systems, it is possible to achieve improvement of pharmacokinetics and pharmacodynamics 
including but not limited to the following aspects: (1) delivery of poor water soluble or very 
short circulating half-life drugs which demonstrates potent biological activity; (2) passive 
targeting or active targeting delivery of drugs to specific tissue or even into the single cell; (3) 
transcytosis of drugs across special biological barriers such as skin or blood brain barrier; (4) 
for combination therapy involving co-delivery of dual or multiple drugs; (5) delivery of 
macromolecular drugs to intracellular sites of action; (6) for other biological applications to 
deliver diagnostic or visualisation agent et al.  
 
Liposomes are the first nanotechnology drug delivery system developed in the 1960s [134]. 
While the first controlled release polymer system for delivery of macromolecules was 
reported in 1976 [135]. The first long circulating liposomes were described in 1987, and the 
concept was later named “stealth liposomes” [136]. After that, the use of polyethylene glycol 
(PEG) and polyesters such as PLA and PLGA was increased in the 1990s. A variety of 
nanotechnology fabricated nanomaterials and devices for drug delivery systems were 





Figure 1.15 Timeline of nanotechnology-based drug delivery. Highlights of some delivery 
systems that serve as important milestones throughout the history of drug delivery. Cited 
from reference [130].  
 
Among them, more than two dozen therapeutic delivery systems have been approved for 
clinical use. Most of the clinical use delivery systems can be divided into either liposomal 
drugs or polymer-drug conjugates [137]. In the future, it is important to continue using 
nanotechnology to develop entirely new therapeutics delivery systems which differ from 





Figure 1.16 Nanotechnology-based synthetic methods: top-down or bottom-up engineering 
of individual components. 
 
Nanotechnology-based synthetic methods are most commonly developed on the basis of two 
rational designs: either top-down or bottom-up engineering of individual components [122, 
139]. The top-down process involves starting with a larger object and breaking it up into 
nanostructures, whiles the bottom-up technique refers to synthesis based on atom-by-atom or 
molecule-by-molecule arrangement in a controlled manner, which is usually regulated by 








methods for fabricating drug delivery systems. Here, the focus is on technologies for 
fabricating nano- or micro-scale polymeric fibres and particles including electrospinning and 
electrospraying which are extensively used in this thesis. 
 
1.3.1 Electrospinning 
Electrospinning is a simple and effective method to fabricate polymer fibres with diameters 
ranging from several nanometres to tens of micrometres [140-146]. The simple procedure, 
possible large-scale production, and wide variety of suitable polymer materials, make 
electrospinning an attractive technique for biomedical applications such as tissue engineering, 
wound repairing, and drug delivery.  
 
1.3.1.1 Electrospinning history 
The term “electrospinning” is derived from electrostatic spinning, which has been extensively 
used since the 1990s [140, 147]. However, the application of electrostatic forces to fabricate 
fibres can be traced back more than two centuries. In 1745, Bose first demonstrated the use of 
high electric potentials to fabricate aerosols.  In 1882, Lord Rayleigh conducted an in-depth 
investigation and calculated the charges number that was required to overcome the surface 
tension of a droplet [148]. At the beginning of the last century, Cooley and Morton developed 
the first device which can use an electrical charge to spray liquids. From 1934 to 1944, Anton 
Formhals described the first experimental setup to use electrostatic forces to generate 
polymeric fibres [149]. Cellulose acetate fibres with small diameters were firstly successfully 




After Formhals, more works have been reported focusing on the better understanding of the 
process of electrospinning. In 1969, Taylor investigated the polymer droplet formation at the 
end of a capillary [151]. When an electric field is applied, the pendant droplet becomes a 
cone due to the electrostatic forces being balanced with the surface tension. This cone is now 
known as “Taylor cone”. Taylor also found that the diameters of the formed fibres are much 
thinner than the diameter of the applied capillary. It is because of the fibre jet is emitted from 
the apex of the core. After Taylor, Baumgarten used a high-speed camera to observe a single 
fibre formation from the droplet. In 1971, Baumgarten firstly conducted the studies on the 
effects of processing parameters and solution properties on the electrospun fibre structures 
[152]. Despite these early investigations, electrospinning had not widely been used until the 
1990s. In the 1990s, the Reneker group rediscovered and spread the investigation and 
application of the electrospinning technology. After that, electrospinning has received 
extensive research interest [153, 154]. 
 
1.3.1.2 Electrospinning setup and parameters 
A typical electrospinning setup consists of three major components: (a) a high voltage power 
supply; (b) a spinneret connected with solution supplier; and (c) a conductive grounded 
collector. This is schematically shown in Figure 1.17. After feeding a polymer solution to the 
spinneret, a droplet of the polymer solution is formed at the tip of the spinneret due to surface 
tension. Application of an electric field between the spinneret and collector adds electrical 
charges to the droplet. It leads to an electrical force directly opposite to the surface tension. 
With increasing voltage of the electric field, the number of surface charges increases until the 
electrical force overcomes the surface tension at which point the liquid polymer solution 
would be ejected towards the collector. During the movement process of the solution, the 
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solvent evaporates and finally polymer fibres would form on the surface of the collector 
[155]. Development of more advanced systems that enable production of core-shell fibres, tri-
axial fibress, multi-tubes fibres, oriented fibres, twisted fibres, and patterned fibres mats can 
be achieved by refitting the spinnerets and/or collectors. 
 
 
Figure 1.17 Schematics of the experimental setup used to perform electrospinning. 
 
Although electrospinning is simple and easy to manipulate, there are still a range of 
processing parameters which can influence the final fibre structure and morphology.  











such viscosity, elasticity, conductivity, and surface tension; (b) governing variables such as 
hydrostatic pressure in the capillary tube, electric potential between spinneret and collector, 
and the distance between the spinneret and collector; (c) ambient parameters such as solution 
and air temperature, humidity, and air velocity in the electrospinning environment [155-157]. 
 
1.3.1.3 Application of electrospinning to drug delivery systems 
Electrospinning has been explored in a wide variety of biomedical application such as tissue 
engineering, drug delivery, and biosensors. Applications in drug delivery for fabrication of 
carriers, electrospinning affords flexibility in materials selections; both biodegradable and 
non-degradable polymers can be electrospun into fibres. Table 1.3 lists the examples of 
synthetic and biopolymers that have been electrospun to produce nano- or micro-scale fibres 
for use in drug delivery. These matrices have been utilized for delivery of a number of drugs 
including antibiotics, anti-inflammatory drugs, anticancer drugs, proteins, DNA, and RNA 
[158]. 
 
For drug delivery applications, electrospun fibres received much attention because of their 
peculiar structures. The thinner fibres possess large surface area to volume ratios. The 
porosity of the fibrous mats dramatically further increases the surface areas. Compared with 
other polymeric structures, it not only overcomes the limitation of high drug uptake, but also 
surmounts the constraint of drug diffusion [159]. This significantly increases the drug release 
efficiency. Besides these, it is easy to control the properties of the electrospun mats such as 




Table 1.3 Examples of electrospun synthetic and biopolymers that have been used for drug 
delivery applications [158-160]. 
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Electrospinning can be used to load drugs by various methods including coating, embedding, 
and encapsulating drugs which lead to well-controlled drug release kinetics. In cases where 
both the polymer matrix and drug are soluble in the same solvent, the drug can be 
incorporated into the polymer by directly dissolving in the polymer solution [160]. When 
they cannot be dissolved in the same solvent, the drug can be dissolved in a solvent that is 
miscible with the polymer solution [161]. By these ways, after the electrospinning, the drug 
would be embedded in the polymeric fibres. The drug can also be encapsulated in the 
polymer using coaxial and emulsion electrospinning [162]. Other popular methods of drug 
loading adopted are: where the electrospun fibrous mats are immersed in a drug solution, or 
surface coating [163]. Therefore, in these two cases, the drug release mechanisms are 





Electrospraying is also another electro-hydrodynamic fabrication method widely applied in 
drug delivery [164-167]. Actually, electrospraying is considered as “sister” technology to 
electrospinning (Figure 1.18). The only difference is that electrospinning is used for nano- 
microfibre fabrication; while electrospraying is used to produce nano- or micro-particles.  
 
As introduced in the electrospinning part, the polymer solution at the tip of the spinneret 
would form a Taylor cone. When the electrostatic repulsion surpasses the surface tension, 
liquid ejection will occur at the surface of the Taylor cone. If the Taylor cone is stable, the 
liquid jet will undergo a whipping or bending motion process, which leads to the formation of 
fibres. However, if the Taylor cone is unstable, the liquid jet will break up into droplets and 
finally form particles [168]. The different properties of the Taylor cone lead to the difference 
between electrospinning and electrospraying.  It also depends on the chain entanglement 
density of the polymer solution [169]. From the perspective of electrospraying, limiting chain 
entanglements will help generate smaller droplets and more uniform microbeads. Chain 
entanglements within the drop eventually limit the subdivision of these drops [170, 171]. 
During the movement of these drops, the solvent evaporates rapidly. Finally, the polymeric 





Figure 1.18 Schematic of the experimental setup used to perform electrospraying. 
 
1.4 Highlights for epilepsy treatment 
According to the World Health Organisation, epilepsy is the world’s most common serious 
brain disorder; it is more than three times as common as multiple sclerosis, Parkinson’s 
disease, and cerebral palsy. It is estimated that around 50 million people in the world have 
epilepsy at any one time [172]. Data from Epilepsy Action Australia shows that 800,000 
people in Australia will be diagnosed with epilepsy at some stage in their lifetime and up to 
5% of the world’s population may have a seizure at some time in their lives. Also, it is 
estimated that over 225,000 Australians are living with epilepsy. Approx. 3% to 3.5% of 











of epilepsy is not only on the person with epilepsy but also the family, and indirectly the 
community is affected. This data and situation highlight the significance to develop effective 
polymeric nano- or micro-structural drug delivery for local treatment of epilepsy. 
 
Therapeutic interventions for epilepsy currently control seizures in only around 70% of 
affected individuals with the remaining people being unresponsive to the current therapeutic 
interventions [174-177]. The reasons for this are not currently well understood, but there is a 
lot of evidence to suggest that a major reason is the presence of blood-brain barrier [175].  
Side effects associated with systemic administration of anti-convulsant drugs include nausea, 
rashes, weight changes and dizziness. These side effects are major factors limiting the drugs’ 
effectiveness in controlling epileptic seizures by preventing the use of higher doses [178-
180]. Development of effective polymeric nano- or micro-structural drug delivery systems 
holds great potential for local treatment of epilepsy. They could be used in the treatment of 
multiple independent foci, as well as treatment of seizure foci in eloquent areas of the brain 
(Figure 1.19). Local direct delivery may also avoid potential problems of whole-brain and 





Figure 1.19 Schematic illustration of local treatment for epilepsy: a) the onset of pre-
seizures; b) progression into an epileptic seizure event; c) implant local drug delivery system 
foci in effective seizure-controlling areas of the brain; d) return to normal situation. 
Reproduced from reference [174].  
 
1.5 Aims and structure of this thesis 
This thesis aims to develop novel structured implantable or injectable drug delivery systems 
for local treatment of central nervous system disorders such as epilepsy.  A variety of 
biodegradable polymer microcapsules and 3D conducting polymer drug delivery systems 





These delivery systems have been systematically characterised, and shown their ability to 
control the release profiles of anti-epileptic drugs.   
 
The investigated biodegradable drug delivery microcapsules will possess controllable and 
uniform morphology with narrow size distribution, high efficiency drug encapsulation, 
sustained and predictable drug release characteristics, and neuro-cytocompatibility. Studies 
will also investigate conducting polymer drug delivery systems that will enable electrically 
controlled properties, sustained near-linear release, flexible dosage control, and super 
stability. Moreover, combined with biodegradable microspheres which contain different 
drugs, two interdigitated electrodes may serve as a multi-functional drug delivery system. 
 
The structure of this thesis is summarised in the following sections: 
Chapter 1 presents the general introduction and related literature review of this research 
field. 
Chapter 2 describes the general experimental method relevant to fabrication, 
characterization, and drug delivery evaluation. 
 
Chapter 3 describes the preparation and characterization of electrojetted PLGA 
microcapsules containing the anti-epilepsy drug, including flattened microspheres, 
microspheres, and microfibres. Different microcapsules lead to the variably controllable drug 
release profiles, and human neural stem cell culture demonstrates the neuro-cytocompatibility 




Chapter 4 describes the development of a series of core-shell structural microcapsules using 
novel core-shell electrojetting. A more hydrophobic polymer shell acts as a barrier 
component to control the rate of drug release from the polymeric core, which leads to 
prolonged drug release profiles. 
 
Chapter 5 investigates the dual drug delivery systems which are composed of electrospun 
microfibres with electrospray microspheres as a composite membrane. These composite 
membranes contain two kinds of drugs, and display stable thermal and mechanical properties, 
and have promising potential for combined therapy. 
 
Chapter 6 describes an electrically on-demand drug delivery system that consists of three-
dimensional printed interdigitated electrodes drug delivery systems coated by 
electropolymerization of a conducting polymer film and electrospray of biodegradable 
polymer microspheres. The interdigitated structure provided flexible drug delivery 
combinations both for mono drug delivery and dual drug delivery systems. 
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In this chapter, the general materials, experimental techniques, and instruments used in this 
thesis are briefly described. These include the reagents list, synthesis methods, 
physiochemical characterization, and in vitro drug release studies. More details regarding 
specific procedures will be presented in the experimental section of each chapter. 
 
2.2 Reagents and materials 
The materials used in this thesis are summarized in Table 2.1. 
 
Table 2.1 Information on Reagents and Materials. 
Name Detailed Information Company 
1. Drug Carriers   
Poly(D,L lactic-co-glycolic 
acid) (85/15) 
Mw ~ 60,000 Da, molar ratio 




Mw ~ 60,000 Da, molar ratio 
of lactide to glycolide 75/25 
Purac, Singapore 
Polylactic acid Mw ~ 180,000 Da Purac, Singapore 
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Pyrrole monomer Fresh distilled before use Sigma-Aldrich 
   
2. Model Drugs   
Lacosamide 
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3. Release Media related   
Phosphate buffered saline Preparation to 0.001M/L Sigma-Aldrich 





Sodium chloride Analytical Reagent Sigma-Aldrich 
Potassium chloride Analytical Reagent Alfa Aesar 
Magnesium chloride Analytical Reagent Alfa Aesar 
Calcium chloride Analytical Reagent Sigma-Aldrich 
   
4. Solvents and others   
Chloroform Chemical Pure Tokyo Chemical Industry 
Dimethylformamide Chemical Pure Sigma-Aldrich 
Methanol HPLC Grade Honeywell 
Acetonitrile HPLC Grade Honeywell 
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Trifluoroacetic acid Analytical Reagent Chemical Supply 
Orthophosphoric acid Analytical Reagent Sigma-Aldrich 
Paraformaldehyde For biological purpose Sigma-Aldrich 





2.3 Fabrication methods 
 






Figure 2.1 Photograph of NANON-01A electrojetting system. 
 
Electrojetting including electrospinning and electrospraying is a simple and versatile 
technique to fabricate nano-/micro- fibre and particle [1-4]. All electrojetting experiments 
were conducted using a NANON-01A electrojetting system which was purchased from 
MECC Co. Ltd, Japan (Figure 2.1). The system is composed of several main parts including 
high voltage power supply, syringe and pump, spinnerets, collector, and Controller panel. 
Both the spinnerets and collectors can be replaced, depending on the application requirement. 
Two kinds of spinnerets are used in this thesis: single tube spinnerets and co-axial spinnerets. 
Two kinds of the collector are used: rotating drum and metal plate. The programming 
controller panel is used to set parameters such as voltage, feeding volume, and rate of the 











NANON-01A system can maintain the electrojetting in a stable atmospheric environment 
with constant temperature and moisture.  
 
2.3.2 Electropolymerization 
Electropolymerization involves the oxidation of the heteroarene to afford radical cations that 
couple to form oligomers. The oligomers precipitate to nucleate polymerization on the 
electrode surface [5, 6]. In this study, electropolymerization was conducted by using a CHI 
600 electrochemical system from CH Instruments, Inc. (Figure 2.2). The instrument contains 
a potentiostat with a potential control range of ±10 V; the current range is ±250 mA. It is also 
available with a wide variety of electrochemical techniques and is capable of integrated 
simulation and fitting software functions for detecting Electrochemical impedance 
spectroscopy (EIS) and Cyclic voltammetry (CV). A standard three-electrode cell with a 
stainless steel mesh counter electrode (CE) and Ag/AgCl reference electrode (RE) were used 
for conducting polymer electrochemical synthesis. The printed 3D Ti-6Al-4V electrode was 
used as the working electrode (WE). The electrodes used in this study were 1 cm by 1cm by 1 




Figure 2.2 Photograph of (A) CHI electrochemical workstation and, (B) schematic of the 
three-electrode system. 
 









2.4.1 Scanning electron microscopy 
Scanning Electron Microscopy (SEM) is used to observe the microstructure of the materials. 
In this thesis, all SEM images were obtained using a JSM7500FA Field Emission Scanning 
Electron Microscope from JEOL Ltd., Japan (Figure 2.3). The sample is dried using a 
vacuum oven at room temperature to remove any residual organic solvent or moisture. 
Typically, the sample is attached to the testing plate with conductive tape. Before SEM 
testing, the nonconductive sample is coated with a thin layer of gold to avoid charge 
accumulation. 
 







2.4.2 Thermogravimetric analysis 
Thermogravimetric Analysis (TGA) is used to investigate the pyrolysis and combustion 
behaviour of the materials [7]. TGA is performed on a TGA Instrument Q500 from TA 
Instruments, UK (Figure 2.4). It can provide information regarding reactions occurring 
during the materials pyrolysis process; such as number and sequence and activation energy 
etc. Typically, the sample weight is ~10 mg, the heating rate is set at 10 
o
C/min, and the TGA 
curves are recorded from 50 to 800 
o
C. In order to eliminate the moisture interference, the 
sample is dried in a vacuum oven overnight before TGA testing. 
 





2.4.3 Tensile testing 
Tensile testing is commonly used to obtain mechanical properties of materials [8]. The 
sample used for tensile testing is typically made into a dog-bone shape, subjected to 
controlled tension until mechanical failure. The result of tensile testing is given as a stress-
strain curve. From this curve, mechanical information such as tensile strength, tensile 
modulus, yield strength (not for all kinds of materials), elongation at break can be 
determined. The tensile testing is performed by using a commercial Shimadzu EZ-L 
mechanical testing machine (Figure 2.5). The sample is gripped by the machine at the two 
ends. It is important to make sure that the sample is held tightly without slippage or failure in 




Figure 2.5 Shimadzu EZ-L mechanical testing machine (A) and dog-bone sample (B). 
2.4.4 Electrochemical impedance spectroscopy 
Electrochemical impedance spectroscopy (EIS) is a powerful diagnostic tool which can be 
used to characterize the interface between the electronic and ionic conductor in 
electrochemical systems [9]. When conducting impedance testing, a frequency response 
analyser is used to impose a small amplitude AC signal to the electrochemical systems and 












Figure 2.6 The three-electrode system with a Luggin capillary for electrochemical testing. 
 
EIS is measured using a Gamry EIS 3000 TM system with Gamry framework software 
employing a three-electrode system (Figure 2.6). The system is made of glass, with a Luggin 
capillary in order to minimize the impact of uncompensated electrolyte resistance [10]. The 
frequency range was from 0.1 Hz to 100 kHz, and the AC perturbation was 5 mV at open 
circuit potential. Data presentation is shown as a Bode Plot in this study. The impedance is 








2.4.5 Cyclic voltammetry 
Cyclic voltammetry (CV) is widely used to study the mechanism, kinetics, electrochemical 
active surface area, and thermodynamics of electrochemical reactions [11]. In cyclic 
voltammetry, the electrode potential ramps linearly versus time as shown in Figure 2.7. 
These ramps can be repeated many times according to experimental requirement. The rate of 
voltage change is the scan rate in mV/s. The potential is applied between the working 
electrode and the reference electrode, and the current is measured between the working 
electrode and the counter electrode. The data is expressed as current vs. applied potential. In 
CV, the current flow is a result of the oxidation/reduction process. It is important and useful 
in the characterization of materials’ electroactivity. In this study, the CV experiment was 
performed using a CHI 600 electrochemical system from CH Instruments, USA. It is tested in 
a three-electrode system, using Ag/AgCl reference electrode and Pt mesh as the counter 






Figure 2.7 The classical triangle waveform used in cyclic voltammetry. 
 
2.5 In vitro drug release study 
 
2.5.1 Passive release study of electrojetted microcapsules 
Drug release study of electrojetted microcapsules including microparticles, microfibres, and 
their hybrid structures is conducted by using a SW23 shaking water bath from John Morris 
Scientific Pty Ltd. The water bath is designed to control the temperature and deliver a smooth 
reciprocal shaking motion (60 rPm). All samples are immersed in aCSF in a glass vial and 
incubated in the shaking water bath. The temperature is set at 37 
o
C. At appropriate time 




2.5.2 Electrically controlled release study of 3D printed electrodes with drug-laden 
coatings 
The electrically controlled release is carried out in a three-electrode system by a using CHI 
600 electrochemical system from CH Instruments, USA. An Ag/AgCl electrode is used as a 
reference electrode; the stainless steel mesh is used as counter electrode. For two 
interdigitated electrodes release study, one electrode is used as the counter electrode. A 
square wave, biphasic voltage stimulation is used for electrical stimulation to trigger drug 
release. The detailed information relating to voltage stimulation is shown in Figure 2.8. After 
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-0.25 V and 0.5 V
Figure 2.8 Applied potentials of the square wave, biphasic voltage stimulations 
used in the electrically controlled release study. 
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2.5.3 High Performance Liquid Chromatography Analysis 
 
Figure 2.9 Photograph of Agilent 1260 Infinity High Performance Liquid Chromatography 
system. 
 
High Performance Liquid Chromatography (HPLC) has wide application in analytical 
chemistry for separation, identification, quantification of chemical components in a mixture 
[12]. HPLC analysis of aCSF containing released drugs was conducted on an Agilent 1260 
Infinity HPLC system (Figure 2.9). The analytical column used here is an Atlantis® T3 C18 
column (5 µm, 250 mm × 4.60 mm). The mobile phase, mobile phase flow rate and the UV-
vis detection wavelength are detailed in each chapter. The amounts of released drugs are 
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calculated according to pre-established calibration curves (Figure 2.10). All the error bars 
data shown in figure are expressed as mean+/- standard division. 
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Approximately 90% of the new drugs that are successful in preclinical studies fail in clinical 
trials[1]. The high failure rate in new drug development is not due to a lack of drug potency, 
but rather due to toxicity, side effects, and poor pharmacokinetics and pharmacodynamics. A 
promising strategy for overcoming these drawbacks is to develop an appropriate drug 
delivery system for targeted and efficient application. For treatment of brain diseases, such as 
epilepsy, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and brain tumours, 
drug delivery to the central nervous system (CNS) represents a unique challenge. This is due 
to a number of factors, in particular the presence of physical permeability barriers such as the 
blood-brain barrier (BBB) and the blood-cerebrospinal fluid (blood-CSF) barrier, and 
expression of multidrug drug efflux transporters at the barriers, which work collectively to 
restrict the entry of many pharmaceuticals into to the brain [2-6]. The low brain permeability 
of many drugs is responsible for drug resistance in the therapies for many diseases. In the 
case of epilepsy, 30-40% of patients remain drug resistant with poor clinical outcomes, and 
this represents a significant hurdle for medication therapy of intractable epilepsy [7]. 
 
In order to deliver drugs to the brain, considerable effort has been made to develop 
nanocarriers for systemic delivery of therapeutics [8-14]. Compared to systemic drug 
delivery, local drug delivery to the site of action offers the potential to improve the 
therapeutic efficacy of epilepsy medication. It directly bypasses the physical brain barriers, 
which may result in improved drug delivery efficiency and bio-distribution. Consequently, a 
lower therapeutic dosage may be required, with a concomitant reduction in side effects [15-
17]. These advantages have motivated the research and development of local drug delivery 
systems for treatment of epilepsy [18-21]. For example, Williamson et al. developed an 
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organic electronic ion pump, composed of poly(3,4-ethylenedioxythiophene) doped with 
polystyrene sulfonate electrodes, for on-demand and site-specific delivery of an inhibitory 
neurotransmitter, gamma-aminobutyric acid (GABA). The delivery of GABA was shown to 
result in quick and localized suppression of epileptiform activity [21]. Pritchard et al. 
developed silk fibroin coatings on solid reservoirs of the anticonvulsant adenosine. By 
modulating the coating thickness and crystallinity, sustained release of adenosine with 
various release profiles including zero-order release profiles was achieved over a period of 
two weeks [19].  
 
Lacosamide, the R-enantiomer of 2-acetamido-N-benzyl-3-methoxypropionamide, is a novel 
antiepilepsy drug. Based on the efficacy and therapeutic index observed in a range of animal 
models of epilepsy at the National Institute of Health (NIH) Anticonvulsant Screening 
Program, lacosamide warranted further evaluation and was subsequently developed as an 
AED for both oral and intravenous use. It is suggested that lacosamide has a dual action 
underlying its anticonvulsant and analgesic properties. It has also been found that lacosamide 
selectively enhances slow inactivation of voltage-gated sodium channels without affecting 
fast inactivation [7]. 
 
This chapter aims to fabricate microcapsules using a simple electrojetting (electrospinning 
and electrospraying) technology, for the sustained delivery of antiepilepsy drugs (AEDs). The 
microcapsules include flattened microspheres, microspheres, and microfibres, which have 
controllable uniform morphology and size distribution, enable high-efficiency drug 
encapsulation, and have release profiles that agree well with the mathematical simulation 
model results, and thus are predictable. Importantly, the microcapsules are compatible with 
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human NSCs (Neural Stem Cells) and derivative neurons and neuroglia, which is indicative 
of clinical compliance for therapeutic use. These microcapsules can be utilized as 




3.2 Materials and Methods 
 
3.2.1 Materials 
The anti-epilepsy drug, lacosamide, was provided by UCB Pharma Pty Ltd. Poly(D,L- lactic-
co-glycolic acid) (Mw ~ 60,000 Da, with a 75/25 molar ratio of lactide to glycolide) (PLGA 
75/25) was purchased from Purac, Singapore. Chloroform, methanol, and acetonitrile were all 
analytical grade from Sigma-Aldrich. All the others chemicals and reagents were purchased 
from Sigma-Aldrich and used as received. 
 
3.2.2 Microcapsule fabrication via electrojetting 
The microcapsules, including microspheres and microfibres, were fabricated using NANON-
01A electrospinning system (MECC Co. Ltd, Japan) at ambient temperature. A range of 
PLGA/lacosamide (w/w, 10/1) solutions were prepared in chloroform, with the PLGA 
concentration varying from 1.5 wt%, 4.5 wt%, to 14.0 wt%, respectively. After encapsulation 
efficiency testing, drug loadings of 8.91 %, 9.20 %, and 9.23 % were achieved. For 
electrojetting, each solution was loaded into a plastic syringe equipped with a 23-gauge 
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stainless steel needle. The distance between the tip of the needle and the aluminium foil was 
12 cm, and the voltage was 10 kV for electrospraying and 21 kV for electrospinning. The 
feed rate was controlled at 0.5 mL/h using a syringe pump, and the electrojetted samples were 
collected using aluminium foil.  
 
3.2.3 Morphological and dimensional statistical analysis 
A field emission scanning electron microscope (FESEM, JEOL JSM-7500FA) was used to 
examine the morphologies of the as-fabricated microcapsules. The samples were sputter-
coated with 20 nm gold prior to SEM testing. The dimensional statistical analysis was 
conducted by quantitatively evaluating the high-magnification SEM micrographs using the 
imaging software, Leica Application Suite. 
 
3.2.4 In vitro drug release study 
The drug release was conducted in artificial cerebrospinal fluid (aCSF) at 37 
o
C in a shaking 
water bath. Each sample was immersed in 1 mL of aCSF, and the released solution was 
removed at various time points and replaced with 1 mL of fresh aCSF.  All samples were kept 
at -20 
o
C, before being analysed by high performance liquid chromatography (HPLC). HPLC 
analysis was conducted using an Agilent 1260 Infinity HPLC system. The analytical column 
used was an Atlantis® T3 C18 column (5 µm, 250 mm × 4.60 mm). The mobile phase 
consisted of Milli-Q water, acetonitrile (HPLC grade) and methanol (HPLC grade) 
(65:26.2:8.8, v/v/v). The mobile phase flow rate was 0.8 mL/min, and the UV-vis detection 
wavelength was 210 nm [20]. The amounts of released drug were calculated according to a 
pre-established calibration curve. An extraction method was used to determine the drug 
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encapsulation efficiencies of the as-fabricated core-shell microcapsules. Briefly, each sample 
(1 cm × 1 cm) was placed into 1 mL methanol for 12 hours, after which the methanol was 
removed and replenished with 1 mL of fresh methanol. This extraction procedure was 
repeated four times, with each methanol sample being allowed to evaporate to leave the 
residual drug behind, which was reconstituted using artificial cerebrospinal fluid (aCSF, 
0.866 wt% NaCl, 0.224 wt% KCl, 0.0164 wt% MgCl2·6H2O, and 0.0206 wt% CaCl2·6H2O in 
0.001M Phosphate Buffer Solution). Each aCSF sample was then analysed for drug content 
using HPLC. The 4th reconstituted sample revealed an absence of the drug, indicating that 
the entire drug had been extracted from the electrojetted sample [22].  
 
3.2.5 Mathematical modelling of the release profiles of the microcapsules 
The release profiles of the microcapsules were simulated using Fick’s second law of diffusion 
subject to appropriate boundary conditions [23, 24]. When the surface resistance to mass 
transfer at the surface is negligible, the fraction of the drug released from the microcapsules 














                              (3.1) 
 
Where, 𝑑 is the diameter of the microcapsules, 𝐷𝑒 is the effective diffusivity of drug, 𝑖 = (2, 
3, 3) and  𝜆𝑛= (nπ) for flattened microspheres and microspheres, 𝜆𝑛= (2.41, 5.52, 8.65, 11.8, 
14.93···) for microfibre[25] (International system od units). The mathematical modelling 




3.2.6 NSC culture and differentiation 
Working stocks of human NSCs (ReNcell CX, SCC007, Millipore) were maintained under 
5% CO2 at 37 
o
C, seeding at a density of 2 – 3 x 10
6 
cells in proliferation medium comprising 
NeuroCult NS-A (#5751, Stem Cell Technologies) with 2 µg/mL heparin, 20 ng/mL FGF2 
and 20 ng/mL EGF (AF-100-15, Peprotech) on laminin (L6274, Life Technologies) coated 6-
well plates (Greiner Bio-One). Cells were passaged at confluency every 5-7 days by digesting 
in TrypLE (Life Technologies) for 3 min at 37 
o
C. Differentiation of NSCs was performed 3 
days after initially seeding in proliferation medium, using neural differentiation medium 
comprising two parts DMEM/F-12 (11330-032, Life Technologies), one part Neurobasal 
(21103-049, Life Technologies) supplemented with 0.5% N2 (17502048, Gibco) and 50 




3.2.7 NSC viability analysis 
PrestoBlue™ cell viability reagent was used for NSC viability studies, according to the 
manufacturer’s instructions. Briefly, cells were incubated with the reagent in culture medium 
for 1 hr at 37 
o
C. Following incubation, for each sample, 100 µL supernatant was transferred 
to a well of a 96-well plate and screened by a microplate reader (POLARstar Omega) to read 
fluorescence intensity. After processing, samples were rinsed in culture medium and returned 




3.2.8 Scanning Electron Microscopy (SEM) 
SEM was performed as previously described [26]. Briefly, samples were fixed in 3.7% 
paraformaldehyde (PFA) for 10 min and then serially dehydrated in 30%, 50%, 70%, 85%, 
95%, and 100% ethanol before Critical Point Drying using a LeicaEMCPD030 instrument. 
The samples were then coated with 20 nm platinum followed by imaging with a JEOL JSM-
7500FA. 
 
3.3 Results and Discussion 
 
3.3.1 Fabrication of lacosamide-loaded microcapsules by electrojetting 
Electrojetting is an electrohydrodynamic process. It is a simple, versatile and cost effective 
technology that employs an electrically charged jet of a polymer solution to fabricate nano- or 
micro- scale fibres (i.e., electrospinning) or particles (i.e., electrospraying) [27-31]. 
Electrojetting is governed by the interactions between the electrostatic repulsion induced by 
an applied electric field and surface tension of a liquid droplet. At the tip of the capillary, due 
to the electrostatic repulsion and the surface tension, the hemispherical surface of the polymer 
droplet is distorted into a conical shape that is known as the Taylor cone. When the 
electrostatic repulsion surpasses the surface tension, liquid ejection will occur at the surface 
of the Taylor cone. Electrospinning (as is illustrated in Figure 3.1) typically occurs when the 
polymer concentration and molecular weight are sufficiently high so that the Taylor cone is 
stable, and the fluid does not break up into droplets but forms a stable liquid jet. The liquid jet 
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Figure 3.1 Schematic illustration of the electrospinning setup, with SEM images of 
electrospun PLGA/lacosamide microfibres. The scale bar is 10 µm. 
 
However, when the polymer concentration is below a threshold and/or the polymer molecular 
weight is low enough, the Taylor cone becomes unstable, and the liquid jet breaks up due to 
varicose instabilities and hence fine droplets are formed. The electrostatic forces among the 
droplets enable self-dispersing of the droplets in space with minimal droplet agglomeration. 

























i.e., the formation of the polymeric microspheres. This process is also  known as 
electrospraying, which is illustrated in Figure 3.2 [32].  
 
 
Figure 3.2 Schematic illustration of the electrospraying setup, with SEM images of 
electrospray PLGA/lacosamide microspheres. The scale bar is 10 µm. 
 
Therefore, under a given electric field, the difference between electrospinning and 
electrospraying lies in the chain entanglement density of the polymer solution [30]. In this 
study, the only variable affecting the chain entanglement density is the PLGA concentration. 


























carefully varying the PLGA concentration in the solutions, three kinds of microcapsules have 
been fabricated, including flattened microspheres, microspheres, and microfibres.  
 
 
Figure 3.3 Scanning Electron Microscope (SEM) images of PLGA/lacosamide a, b) 
Flattened microspheres, c, d) Microspheres. 
 
Here shown are the SEM micrographs of lacosamide-loaded flattened microspheres (obtained 
from 1.5 wt% PLGA and at 10 kV), microspheres (obtained from 4.5 wt% PLGA and at 10 
kV), and microfibres (obtained from 14 wt% PLGA and at 21 kV). Our study shows that 
electrospraying led to the formation of either flattened microspheres or microspheres (Figure 













Figure 3.4 Scanning Electron Microscope images of PLGA/lacosamide Microfibres. 
These results are consistent with the previous studies, where the polymer concentration is 
demonstrated to be the most critical parameter in determining the morphology of electrojetted 
microcapsules [24, 30]. In the current study, at a low PLGA concentration such as 1.5 wt% 
and 4.5 wt%, even with an increased applied voltage of up to 21 kV, only micro-spherical 























Evaluation of the dimensional and shape uniformity was conducted by analysis of the SEM 
images of the as-prepared microcapsules. As shown in Figure 3.5, the diameters are 
3.01±0.51 µm for the flattened microspheres, 5.10±0.78 µm for the microspheres, and 























Figure 3.5 Size of flattened microspheres, microspheres, and microfibres. 
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microcapsules is shown in Figure 3.6, respectively. All the as-fabricated microcapsules 
demonstrate uniform morphology with narrow size distribution.  
 
 
Figure 3.6 Size distributions of flattened microspheres, microspheres, and microfibres. 
. 
For electrospinning, as the PLGA concentration is high at 14 wt%, sufficient polymer 
entanglements are present and responsible for the formation of a stable liquid jet of PLGA 
that undergo continuous stretching during the whipping or bending motion process. 
Compared to the microcapsules produced by electrospray, the diameters of the electrospun 
microfibres are much thinner [33]. 
































































Figure 3.7 Aspect ratio of PLGA/lacosamide a, b) flattened microspheres and c, d) 
microspheres; Aspect ratio defined as the ratio of the l to w as shown in figures. 
 
For electrospraying, the dimension and shape of the microcapsules are controlled by these 
two processes: rapid solvent evaporation of the droplets, and polymer diffusion during 
evaporation. However, rapid solvent evaporation and polymer diffusion do not necessarily 
lead to spherical microspheres. When a lower PLGA concentration, such as 1.5 wt%, was 
used in this present work, flattened morphology is formed. This is probably due to incomplete 
solvent evaporation, as such the electrosprayed microcapsules are still in liquid form when 














formation of spherical microspheres with increased particle sizes; since increasing the 
polymer concentration leads to an increase in the solution viscosity and a reduction in the 
surface tension. In accordance with Hartman’s study, decreasing the surface tension results in 
increasing the size of electrospray PLGA microspheres [35].  
 
Figure 3.8 Statistical results of aspect ratio, a) flattened microspheres and b) microspheres. 
Aspect ratio (AR), expressed as l to w (shown in Figure 3.7), is an important parameter to 
evaluate the shape uniformity of the particles. The dimensions of flattened microspheres and 





















































1.03 for the microspheres, and 1.05 for the flattened microspheres (Figure 3.8). Both kinds of 
microcapsules possess excellent shape uniformity. 
 













As shown in Figure 3.9, all the microcapsules exhibit ultra-high drug encapsulation 
efficiency. They are 89.1±6.9 % for flattened microspheres, 92.0±3.5 % for microspheres, 
and 92.3±2.1 % for microfibres. These encapsulation efficiencies are significantly greater 































Figure 3.9 Drug encapsulation efficiency of PLGA/lacosamide flattened 
microspheres, microspheres, and microfibres. 
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polymerization [36], solvent evaporation [36, 37], spray drying [38], and layer-by-layer 













Figure 3.10 shows the in vitro drug release profiles of the flattened microspheres, 
microspheres, and microfibres. The release profiles vary significantly with the shape and 
morphology of the microcapsules. While the microfibres demonstrate the least initial burst 
release, the flattened microspheres exhibit the most rapid release characteristics, with more 
than 95% of the lacosamide being eluted within ~52 hours. Within the same period, the 
cumulative release of the lacosamide from the microspheres and microfibres is approximately 
74% and 55% of the respective total drug loading.  


































From the perspective of clinical application, for short term seizure prophylaxis, such as after 
brain surgery, quick early release to a therapeutic level would be preferred. However, the 
microfibres are more clinically useful as they afford a longer duration of release. An ideal 
implantable seizure control device should further improve the kinetics to provide as even and 
as long-term release as possible over the duration of the implant [18]. The fabrication 
methods demonstrated here have the potential for further improvement after easy 
modification. For example, application of core-shell spinnerets to fabricate core-shell 
microfibres can significantly prolong release time [16]. Besides these, use of a more 
hydrophobic polymer as drug carrier is another promising option. 
 
Typically, drug release from biodegradable microcapsules is controlled by diffusion at an 
initial stage and then a combination of diffusion and erosion at the later stage [40]. During 
incubation in the release medium, drug diffusion occurs initially within a thin surface layer, 
and subsequently with water penetration into the bulk of the microcapsules, enhanced 
diffusive transport of the remaining lacosamide in the microcapsules occurs. Therefore, the 
morphology and dimension of the PLGA microcapsules have a significant influence on the 
release of lacosamide. Most of the reported mathematical modelling studies for biodegradable 
microcapsules drug delivery systems are based on a single, zero-order process; or a process 
that is governed only by diffusional mass transfer or chemical reactions [41]. In order to more 
accurately predict drug release kinetics for biodegradable microcapsules, mathematical 
models that take account of the effects of composition and geometry (size and shape) on the 




In this study, it is assumed that drug release from those microcapsules is predominantly 
diffusion-controlled within the period of study. This assumption is based on our and others’ 
in vitro studies that showed minimal polymer degradation of the microcapsules within a 
period of up to three weeks [20, 24, 41]. According to Fick’s second law of diffusion, the 
fraction of the released drug from the microcapsules (Mt/M∞) at any time (t) can be expressed 
as equation (1). In this model, a well-mixed external aqueous phase with a negligibly small 
drug concentration is assumed. And the drug is assumed to be homogeneously distributed 
throughout the polymer matrix with an initial drug concentration higher than the solubility of 
the drug in the polymer. For the microfibres geometry, the drug diffusional release is 
considered from a cylindrical matrix. The eigenvalues 𝜆𝑛 , the roots of eigenfunctions are  
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For the flattened microspheres and microspheres geometry, the diffusional drug release is 
considered from a spherical matrix. The eigenvalues 𝜆𝑛, the roots of eigenfunctions are 𝑛𝜋. 






















Figure 3.11 Comparison of the mathematical modelling results (linear) with experimental 
drug release profiles (dots). 
 
Figure 3.11 shows the least-squares fitting results by applying these mathematical models. 
The initial drug loading is determined by encapsulation efficiency testing results of HPLC. 
Our results demonstrated that drug release profiles using the above models could be predicted 
with a very good agreement with the experimental drug release data. The computed effective 













/min for microfibres, well within the range of values 
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previously reported for hydrophobic drugs in PLGA microcapsules [23]. Compared with the 
flattened microspheres and microspheres, the microfibres possess the lowest effective 
diffusivities (𝐷𝑒) during this time-dependent diffusion process.  
 
3.3.4 Human neural stem cell viability and differentiation 
 
 
Figure 3.12 Human NSC viability and on a) microfibres and b) microspheres. NSCs were 








Demonstration of neuro-cytocompatibility of these electrojetted spheres and fibres was 
carried out by using clinically relevant human brain tissue derived NSCs and their 
differentiation to neurons and supporting neuroglia.   
 
 
Figure 3.13 Human NSC viability and proliferation kinetics during culture with microfibres 
and microspheres. 
 
Neurocompatibility was supported by cell attachment (Figure 3.12) and viability (Figure 
3.13) during extended cell culture with fibres and spheres. NSC viability studies indicated 





Figure 3.14 Morphology of differentiated human NSCs during culture with microfibres and 
microspheres. 
 
In all cases, quantitative measurement of cell viability marker PrestoBlue® supported normal 
growth kinetics, with cell proliferation increasing exponentially up to 8 days culture. As 
expected, cell viability decreased following peak cell growth, reflecting the limits of culture 














Figure 3.15 Morphology of differentiated human NSCs during conventional plate-based 









Figure 3.16 Immunophenotyping of differentiated NSCs. DAPI (blue) colocalised with 
neuronal markers MAP2 (green), and TUJ1 (red), and glial marker GFAP (purple) expressed 
by differentiated NSCs cultured with microspheres. scale bar: 50 µm. 
 
Importantly, differentiation of NSCs resulted in neuronal cells cultured for up to 10 days with 







successful differentiation and co-culture of spheres and fibres with MAP2 and TUJ1 
expressing neurons (Figure 3.16) and GFAP expressing glial cells (Figure 3.17).  
 
Figure 3.17 Immunophenotyping of differentiated NSCs. DAPI (blue) colocalised with 
neuronal markers MAP2 (green) and TUJ1 (red), and glial marker GFAP (purple) expressed 











In conclusion, microstructured drug delivery systems have been fabricated by using a simple 
electrojetting (electrospraying and electrospinning) technology for local delivery of AEDs. 
These microcapsules have demonstrated a number of advantages, including controllable and 
uniform morphology and narrow size distribution, high efficiency drug encapsulation, 
sustained and predictable drug release characteristics, and neuro-cytocompatibility as 
evidenced by human NSC support and differentiation. Our findings broadly support the 
utility and efficacy of the local drug delivery systems for treating human brain disorders such 
as epilepsy. In addition, the method presented here could be applicable to the fabrication of 
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Epilepsy is a long-term neurological disorder, affecting more than 60 million people 
worldwide. It is characterized by recurrent and unpredictable seizures, which can cause loss 
of consciousness, falls and injury, psychosocial disability, and even mortality. Medication 
provided via oral administration is the first approach to epilepsy treatment, but controls only 
up to 70% of the cases, whilst the rest of the patients remain incompletely responsive to 
medication [1, 2]. The reasons for this are not yet fully understood, but there is a significant 
body of evidence pointing to the blood-brain barrier (BBB) [3]. The BBB protects the brain 
from harmful blood-borne substances and microorganisms by separating the brain 
parenchyma from the circulating blood. Such self-protection also poses an obstacle to drug 
delivery to the brain. Nearly 100% of high molecular weight drugs and >98% of low 
molecular weight drugs are excluded from the brain [4-6]. For instance, a typical dosage of 
an antiepilepsy drug (AED), such as lacosamide (used in this study), is 400 - 500 mg per day 
[7, 8] by oral administration. However, the actual amount of lacosamide arriving at the sites 
of seizures is very limited due to the limited ability of the drug to cross the BBB [3]. 
Moreover, this high systemic dosage causes serious whole body side-effects, such as rashes, 
nausea, and weight changes. 
 
For patients whose seizures cannot be controlled by medications, surgery represents an 
alternative option, which can be provided only to appropriately selected patients, where the 
seizure origin in the brain can be localized. In addition, a comprehensive pre-surgical 
assessment must be conducted in order to ensure the benefits of the operation. Following 
surgical therapy, the patients still need to take AEDs for a long time to prevent epilepsy 




To improve epilepsy control, local drug delivery through microinjection or implantation in 
the brain to bypass the BBB may offer an innovative approach to improve the efficacy of the 
medication. This approach can significantly reduce the dosage of AEDs, while concurrently 
minimising the side effects associated with systemic administration of AEDs [11, 12]. In 
addition, compared to surgical resection, direct injection or implantation would significantly 
reduce potential brain damage [13]. 
 
An ideal local drug delivery system should be biocompatible, biodegradable and exhibit an 
optimal drug release profile pertaining to the targeted application. It should also be amenable 
to fabrication and large scale production. Poly(lactic-co-glycolic acid) (PLGA) has been 
intensively studied for local drug delivery [14-16]. In particular, it has been explored in 
treating central nervous system disorders, such as Alzheimer’s [17, 18] and Parkinson’s [19, 
20] diseases, as well as in treating brain injury [21], demonstrating excellent brain 
biocompatibility. Lacosamide was selected as a model drug based on its efficacy and 
therapeutic index [22]. In terms of material fabrication, electrojetting, such as electrospinning 
and electrospraying, has attracted tremendous interest in recent years [23-28]. It is a low-cost 
and versatile technique for uniform fabrication of polymer structures ranging from nanoscale 
to microscale [29-31]. However, only limited studies have been undertaken on the 
electrojetted systems in terms of morphology, drug encapsulation efficiency and drug release 
characteristics [31, 32]. Moreover, to the best of our knowledge, no study has yet to be 
reported on core-shell structured electrojetted systems. 
 
This chapter aims to apply a novel electrojetting technique for the fabrication of core-shell 
microspheres and microfibers, where AED-laden polymer cores are surrounded by drug-free 
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polymer shells that act as a barrier in order to regulate drug release characteristics. A variety 
of core-shell PLGA/lacosamide microcapsules, including microflakes, flattened 
microspheres, microspheres, microsphere-fibres, beaded microfibres, and microfibres, have 
been developed with narrow size distribution and uniform morphology. These systems 
demonstrated high efficiency in drug encapsulation and sustained drug release characteristics, 
which makes them promising candidates as injectable microspheres and polymer implants for 
local drug delivery for epilepsy control. 
 
4.2 Materials and methods 
 
4.2.1 Materials 
Poly(D,L-lactic-co-glycolic acid) (PLGA) (Mw ~ 60,000 Da) with various molar ratio of 
lactide to glycolide, including PLGA 75/25 (lactide/glycolide = 75/25) and PLGA 85/15 
(lactide/glycolide = 85/15), were purchased from Purac, Singapore, and used as received. 
Lacosamide, an anti-epilepsy drug, was provided by UCB Pharma Pty Ltd. All the other 
chemicals and reagents were purchased from Sigma-Aldrich. 
 
4.2.2 Electrojetting (electrospinning and electrospraying) 
A range of solutions of PLGA 75/25 and lacosamide were prepared as the core solutions for 
electrojetting. In these solutions, the ratio of polymer/drug (w/w) was kept constant at 10/1, 
while the polymer concentration was varied from 0.75 to 15 wt%. After encapsulation 
efficiency testing, drug loadings of 9.06 %, 9.11 %, 9.40 %, 9.53 %, 9.49 %, and 9.92 % were 
achieved. A range of drug-free PLGA 85/15 solutions were prepared as the shell solutions for 




Electrojetting (electrospinning and electrospraying, respectively) was conducted at room 
temperature using a NANON-01A electrospinning system (MECC Co. Ltd, Japan). A coaxial 
spinneret with 0.2 mm core and 0.8 mm sheath nozzles were connected to the core 
and shell solutions. The distance from the spinneret tip to the collector was maintained at 12 
cm, and the applied voltage for electrospinning and electrospraying was 21 kV and 10 kV, 
respectively. The feed rate was 0.1 mL/h for the core solutions and 0.4 mL/h for the shell 
solutions. Aluminium foil was used to collect the fabricated core-shell microcapsules, and the 
samples were further dried in a vacuum oven at room temperature for 48 hours to remove any 
residual organic solvent. 
 
4.2.3 Morphological and dimensional statistical analysis 
The morphologies of the as-prepared microcapsules were examined using a Field Emission 
Scanning Electron Microscope (FESEM, JEOL JSM-7500FA). The samples were sputter-
coated with 20 nm gold to avoid charge accumulation. The dimensional statistical analysis 
was conducted by analysis of the SEM micrographs using the imaging software, Leica 
Application Suite. All data were expressed as mean ± standard deviation (SD). 
 
4.2.4 Determination of drug encapsulation efficiency  
An extraction method was used to determine the drug encapsulation efficiencies of the as-
fabricated core-shell microcapsules. Briefly, each sample (1 cm × 1 cm) was placed into 1 
mL methanol for 12 hours, after which the methanol was removed and replenished with 1 mL 
of fresh methanol. This extraction procedure was repeated four times with each methanol 
sample allowed to evaporate to leave residual drug behind. And the methanol extracts were 




The details of the HPLC testing method were refer to previous work [33]. The amounts of 
released drug were calculated according to a pre-established calibration curve that was 
obtained by plotting the peak areas against respective concentrations of a range of standard 
lacosamide solutions prepared in aCSF. 
 
4.2.5 In vitro drug release study 
In vitro drug release was conducted in artificial cerebrospinal fluid (aCSF). Each sample (1 
cm × 1 cm) was incubated in 1 ml of aCSF at 37 
o
C in a shaking water bath. At appropriate 
time intervals, the release medium was withdrawn and replaced with 1mL of fresh aCSF. The 
released samples were stored at -20 
o
C prior to the HPLC analysis for quantification of the 
amounts of the lacosamide released. The results were shown as cumulative release vs time. A 
line was used to connect the sample dots of the appropriate time intervals. The results were 
quite different from the modelled data presented in Chapter 3. 
 
4.3 Results and Discussion 
 





Figure 4.1 Schematic illustration of the electrojetting setup, electrospinning of core-shell 
microfibres. 
 
Electrojetting, including electrospinning and electrospraying, represents a simple and 
versatile method for producing monodisperse polymeric spheres and fibres at the nano- and 
micro-scale [23, 34]. Electrojetting is governed by the interactions between the electrostatic 
repulsion induced by an applied electric field and surface tension of a liquid droplet. When 
the electrostatic repulsion surpasses the surface tension to a critical point, liquid ejection will 
occur at the surface of the droplet. The liquid jet will undergo a whipping process, which 
leads to the formation of either fibres (electrospinning, as shown in Figure 4.1), or spheres 
(electrospraying, as shown in Figure 4.2) at the nano- or micro-scale. Therefore, the final 
electrojetted structure is determined by the electric force applied and the properties of 
polymer solutions. The polymer solution properties are governed by the molecular weight 




















Figure 4.2 Schematic illustration of the electrojetting setup, electrospraying of core-shell 
microspheres. 
 
In this study, PLGA 75/25 and lacosamide were used as the core structural materials, whilst 
PLGA 85/15, a  more hydrophobic copolymer, was used as the shell material [35]. 
Chloroform was used as the solvent, with a low boiling point of 61.2 
o
C. By adjusting the 
applied voltage and screening of the concentrations of the core and shell solutions, 
microcapsules with various shapes, including microflakes, flattened microspheres, 































Applied Voltage      
(kV) 
Type of microcapsule 
formed 
S0w 0.75 0.5 10 Microflakes 
S2w 3 2 10 Flattened microspheres 
S4w 6 4 10 Microspheres 
S5w 7.5 5 10 Microspheres-fibres 
S8w 12 8 21 Beaded microfibres 
S10w 15 10 21 Microfibres 
 
These microstructures, together with their respective fabrication conditions, including the 
concentrations of the core and shell solutions and voltage, are summarised in Table 4.1. For 
electrospraying of microflakes, flattened microspheres, microspheres or microspheres-fibres, 
a 10 kV voltage was used, whereas for electrospinning of beaded microfibres or microfibres, 
a 21 kV voltage was used. 
 





Figure 4.3 Scanning Electron Microscope (SEM) images of various core-shell PLGA 
microcapsules; a, b) Microflakes, c, d) Flattened microspheres, e, f) Microspheres. 
 
During the electrojetting process for fabrication of the microflakes or flattened microspheres, 
both the polymer concentrations in the core and shell solutions are very low (Table 4.1). This 
results in the rapid collapse of PLGA microcapsules during solvent evaporation and polymer 















(Figure 4.3 c,d) with a rough, pitted and porous surface topography [36]. At higher PLGA 
concentrations, such as 6 wt% of the core solution and 4 wt% of the shell solution, 
microspheres (Figure 4.3 e,f) are produced, exhibiting a much smoother surface.  
 
 
Figure 4.4 Scanning Electron Microscope images of various core-shell PLGA a, b) 
Microspheres-fibres, c, d) Beaded microfibres. 
 
Further increasing the PLGA concentrations to 7.5 wt% for the core and 5 wt% for the shell 
results in the concurrent formation of microspheres and microfibres (Figure 4.4), where the 
diameters of fibres are much thinner than those of the microspheres. The portion of the 













Figure 4.5 Scanning Electron Microscope images of various core-shell PLGA a, b) 
Microfibres. 
When the polymer concentration reaches 15 wt% for the core and 10 wt% for the shell, only 









Figure 4.6 Schematic illustration of the detection points of the sizes of the fabricated core-
shell microflakes, flattened microspheres, microspheres, microspheres-fibres, beaded 
microfibres, and microfibres. The d is from the detection points as shown in figure. 
 
Our work demonstrates the critical roles of both the polymer concentrations of the core and 
shell solutions in controlling the shape and morphologies of the electrojetted core-shell 
















microcapsules that were produced by electrojetting a single solution and thus do not possess 
the core-shell structures [31].  
 
In order to evaluate the shape, size and size distribution of the as-prepared microcapsules, a 
Leica Application Suite was used to analyse the SEM images. The detection points of the 

















The sizes of the microflakes, flattened microspheres, microspheres, microspheres-fibres, 
beaded microfibres, and microfibres are presented in Figure 4.7. The size distributions of 










































Figure 4.7 Size of the core-shell microflakes, flattened microspheres, microspheres, 

























Each type of the electrojetted core-shell microcapsules exhibits a narrow size distribution and 
uniform morphology. With an increase in the PLGA concentrations, the dimension of the 
respective microcapsules firstly increased, and then decreased in the case of microfibres. The 

































































































































Figure 4.8 Size distribution of each type of core-shell microcapsules. 
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diameters are 2.26±0.67 µm for the microflakes, 2.67±0.46 µm for the flattened 
microspheres, 4.42±1.08 µm for the microspheres, 5.35±0.94 µm for the microspheres-fibres, 
7.02±1.45 µm for the beaded microfibres, and 1.11±0.43 µm for the microfibres, 
respectively.  
 
In accordance with Hartman’s study [37], the dimension of PLGA microspheres formed 
using electrospraying is governed by  the surface tension of the polymer solution, as shown in 






)1 6⁄  (4.1) 
 
Where 𝑑 is the droplet size, 𝜌 is the density of solution, 𝜀0 is the permittivity of vacuum, 𝑄 is 
the liquid flow rate, 𝛾 is the surface tension of solution in ambient air, and 𝐾 is the liquid 
conductivity (International system od units). Increasing the polymer concentration leads to an 
increase in the solution viscosity, and a reduction in the surface tension(𝛾), and consequently 
an increase in microsphere size (d) (Equation 4.1) [37]. When the polymer concentration 
becomes sufficiently high, the solution can endure continuous and longer stretching from the 
nozzle tip to the collector, which gives rise to much thinner microfibres through the 











Figure 4.9 Drug encapsulation efficiency of the core-shell microflakes, flattened 
microspheres, microspheres, microspheres-fibres, beaded microfibres, and microfibres. 
 
It is shown in Figure 4.9 that all the fabricated core-shell microcapsules exhibit  90% drug 
encapsulation efficiencies. The core-shell microfibres demonstrate the highest drug 
encapsulation efficiency (99.2±5.4%). These encapsulation efficiencies are greater than those 
prepared using other techniques, including emulsion, suspension, and emulsion 
polymerization [38], solvent evaporation [38, 39], spray drying [40], layer-by-layer [41]. This 
can be ascribed to i) the inherent core-shell structures where the drug is encapsulated in the 
core and further protected by a shell of more hydrophobic polymer and ii) the fast 
solidification of the microcapsules at room temperature due to the use of a low boiling point 




4.3.4 In vitro drug release study 
The representative in vitro release profiles of lacosamide from the fabricated PLGA 





Figure 4.10 Cumulative release of lacosamide from the fabricated core-shell PLGA 
microcapsules including microflakes, microspheres, microspheres-fibers, and microfibers in 







The sustained release characteristics demonstrated by all the microcapsules could be 
attributable to their core-shell structures, where the drug-free polymer shells present an 
additional barrier to the drug elution from the core [35]. The release profiles varied 
significantly with the shape and morphologies of the microcapsules. The microflakes 
exhibited the most rapid release characteristics, with > 96% of the encapsulated lacosamide 
being eluted within ~43 hours. Within the same period, the cumulative release of the 
lacosamide from the microspheres, microspheres-fibres, and microfibres, was approximately 
75%, 60%, and 35% of the respective total drug loading. Compared to the microflakes, 
microspheres, and microsphere-fibres, microfibres exhibited significantly less initial burst 
release. 
 
Figure 4.11 The release profiles of the core-shell microcapsules including microflakes, 




It is also noted that there is no significant mass loss in the microcapsules after a prolonged 
incubation in aCSF (104 days), other than that arising from the drug elution. This suggests 
minimal polymer degradation of the electrojetted microcapsules taking place within this 
period, which also indicates that the drug release from these microcapsules is predominantly 
diffusion controlled. The morphology and dimension of the PLGA microcapsules had a 
significant influence in the lacosamide release characteristics.  
 
 







For the microcapsules with dominant sphere/particulate shape, including microflakes, 
microspheres, microspheres-fibres, the release rate decreased with increasing microcapsule 
dimension (Figure 4.7 and Figure 4.11). With an increase in the sizes of the microcapsules, 
the surface area to volume ratios of the microcapsules decrease, and this leads to slower water 
penetration rates into the microcapsules and thus slower drug release profiles. Compared with 
the microspheres (Figure 4.12) and microfibres (Figure 4.13) without core-shell structure, 
the core-shell structured microspheres and microfibres exhibit significantly slower release.  
 
 






These microcapsules can serve as injectable microparticulate systems or polymer implants, 
for the local pharmaceutical intervention of epilepsy, as well as treatments for other 
neurological disorders, such as Parkinson’s disease, Huntington’s disease, and Alzheimer’s 
disease. Compared with the systemic administration that requires high dosages, local 
implantation or injection using these drug-eluting microcapsules can significantly reduce the 
dosage and side effects. Moreover, these drug release studies demonstrate that the daily 




In summary, a variety of core-shell structured PLGA microcapsules containing an anti-
epilepsy drug, lacosamide, have been fabricated by a novel electrojetting technique. These 
microcapsules, including microflakes, flattened microspheres, microspheres, microspheres-
fibres, beaded microfibres, and microfibres, all demonstrated narrow size distribution and 
uniform morphology, high efficiency of drug encapsulation and sustained drug release 
characteristics. The release profile of lacosamide varies with the morphologies and shape of 
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5. CHAPTER 5: DEVELOPMENT OF 
ELECTROSPUN AND 
ELECTROSPRAYED DUAL DRUG 









The packaging and delivery of drugs to a specific location in the human body via 
biomaterials systems has been approaching the forefront of biomedical research for the past 
few decades [1-5]. Most of the drug delivery systems have been developed focusing on the 
achievement of mono drug release by developing a wide variety of biomaterial carriers. 
However, there are many situations that require multiple medications. Combination therapy 
with drugs of different therapeutic effects provides an effective strategy in the treatment of 
diseases [6]. Studies also show that combined therapy with two or more drugs provides a 
promising strategy to suppress drug resistance as different drugs possess different therapeutic 
effects at various pathological stages [7]. A variety of drug combinations can induce 
synergism and have shown promise in preventing disease recurrence [8-13]. 
 
One major challenge of combination therapy is to ensure effective dose for each drug 
independently. In order to overcome this challenge, one of the most popular approaches is to 
load multiple therapeutic agents into one delivery system and then concurrently deliver them 
to the site of action [8, 12, 14, 15]. A number of such drug delivery systems, including 
nanoscale and microscale particles, have been developed, for delivery of multiple drugs. 
However, fine control of the dosage and release kinetics remains a challenge. Besides, the 
complexity of the materials for use in the human body creates additional regulatory 
challenges. In addition, our limited understanding of the interactions between these new 
synthesis compounds and the body, especially the diseased part environment presents hurdles 
[1, 16]. The complicated fabrication process also makes it difficult to mass produce and apply 





This chapter aims to use combinatorial electrospinning and electrospraying, to fabricate 
composite matrices as dual drug delivery vehicles. The composite structures of fibrous 
matrices with microparticles dual drug delivery systems demonstrated well-controlled 
internal structures, with uniform morphology and favourable thermal and mechanical 
properties. The drug release study shows that the daily dosage and release kinetics of these 
systems can be tailored by varying the shape and size of the polymeric carriers. In addition, 





Poly(D,L lactic-co-glycolic acid) (PLGA) with a molar ratio of lactide to glycolide, 75 to 25, 
and polylactic acid (PLA), were purchased from Purac, Singapore, and used as received. The 
anti-epilepsy drug, lacosamide, was provided by UCB Pharma Pty Ltd. Phenytoin and 
dexamethasone were purchased from Sigma-Aldrich. All the others chemicals and reagents 
not mentioned above were purchased from Sigma-Aldrich and used as received without 
further purification. 
 
5.2.2 Fabrication of Composite matrices 
The polymer solutions for electrosprayed spheres were prepared by dissolving PLA and 
PLGA separately with the drug in chloroform. And the polymer solution for electrospun 
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fibres was prepared by dissolving PLA and drug in chloroform/DMF (volume ratio, 4/1). The 
solvent and a mixture solvent of the electrospinning and electrospraying conditions were 
optimized to obtain bead-free PLA fibres and uniform spherical PLA, PLGA spheres. In 
these solutions, the ratio of polymer/drug (w/w) was kept constant at 10/1, while the polymer 
concentration varied from 0.75 to 9.6 wt%. After encapsulation efficiency testing, drug 
loadings were achieved, which were 9.72 % for PLA phenytoin microfibres, 9.06 % for 
PLGA lacosamide microspheres, 9.35 % for PLA lacosamide microfibres, and 9.10 % for 
PLGA dexamethasone microspheres. 
 
Composite dual drug delivery systems were formed by combinatorial electrospinning and 
electrospraying from two opposing spinnerets onto a rotating mandrel at room temperature 
[17, 18]. The solutions were loaded into plastic syringes with 23-gauge stainless steel needle 
independently. For electrospinning microfibres, the injection rate was 0.3 mL/h, the applied 
voltage was 21 kV, and the distance from the tip of the needle to collector mandrel was 15 
cm. For electrospraying microspheres, the injection rate was 0.5 mL/h, the applied voltage 
was 10 kV, and the distance from the tip of the needle to collector mandrel was 12 cm. The 
rotation speed of the mandrel was set as 0.2 m/s. The low enough rotation speed can prevent 
microfibres alignment [19]. In order to obtain a homogeneous mixture of the microfibres and 
the microspheres, a dielectric tap was attached to the rotating mandrel to delimit the 
deposition area. The charged electrospraying microspheres are very sensitive to the 
electrostatic field  and can be confined with a dielectric tap [18]. In order to remove possible 
residual organic solvent, all the samples were further dried in a vacuum oven at room 




5.2.3 Characterization and evaluation 
A Field Emission Scanning Electron Microscope (FESEM, JEOL JSM-7500FA) was used to 
examine the morphologies of the as-fabricated microcapsules. Before the SEM examination, 
the specimens were sputter-coated with gold to avoid charge accumulation. Dimensional 
statistical analysis was conducted by analysis of the SEM micrographs using the imaging 
software, Leica Application Suite. All data were expressed as the mean ± standard deviation 
(STDEV). Thermogravimetric analyses (TGA) were carried out by using Q500 (TA 
Instruments), the heating rate was set at 10 
o
C/min, and the TGA curves were recorded from 
50 to 800 
o
C under 15 ml/min flow of N2. The amounts of samples for the TGA analyses 
were ~ 10 mg to avoid possible thermal lag. For testing the mechanical properties of 
composite matrices, the prepared matrices were cut into standard dumbbell-shaped 
specimens, and the test was performed by using a commercial mechanical Shimadzu EZ-L 
testing machine at the crosshead speed of 5 mm/min. Five specimens were tested for each 
sample, and the average values with respective standard deviations were calculated.  
 
5.2.4 In vitro drug release study and quantification of drug encapsulation efficiency 
In vitro drug release was conducted in artificial cerebrospinal fluid (aCSF) at 37 
o
C in a 
shaking water bath. At appropriate sample time, the release medium was withdrawn and 
replaced with equal amount of fresh aCSF. The released samples were analysed using the 
HPLC to determine the amounts of drug released. 
 
HPLC analysis was conducted using an Agilent 1260 Infinity HPLC system. The analytical 
column used was an Atlantis® T3 C18 column (5 µm, 250 mm × 4.60 mm). The testing 
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parameters for the three drugs are summarised in Table 5.1. The amounts of released drug 
were calculated according to a pre-established calibration curve in aCSF [20-22]. The drug 
encapsulation efficiency was determined by using an extraction method according to our 
previous work [17]. Briefly, each sample (1 cm × 1 cm) was placed into 1 mL methanol for 
12 hours, after which the methanol was removed and replenished with 1 mL of fresh 
methanol. This extraction procedure was repeated four times, with each methanol sample 
being allowed to evaporate to leave the residual drug behind, which was reconstituted using 
aCSF. The drug content was then analysed using HPLC as described above. 
 
Table 5.1 HPLC testing parameters for the drugs including mobile phase, UV-Vis detection 
wavelength, and mobile phase flow rate. 




Lacosamide Milli-Q water, acetonitrile, and 
methanol (65:26.2:8.8) 
210 0.8 
Phenytoin Milli-Q water and acetonitrile (50:50) 203 1.4 
Dexamethasone 
 
Milli-Q water and acetonitrile (35:65) 





5.3 Results and Discussion 
5.3.1 Fabrication and selection of proper component 
The process parameters including choosing of polymer, preparation of the solution, 
conditions of electrospinning and electrospraying et al. were optimized in order to achieve 




Figure 5.1  Scanning electron microscope images of electrosprayed PLA erythrocyte-like 
microspheres. 
 
As discussed in chapter 3, the electrojetted polymeric structures mainly depend on the 
polymer concentration and electrojetting parameters. Here, the focus is on discussion of the 
fabrication of PLA microspheres and microfibres. Similarly, by adjusting the polymer 
concentration and electrospraying parameters, erythrocyte-like PLA microspheres (Figure 
5.1) were obtained. They were prepared using a polymer concentration of 0.75 wt%. All these 
erythrocyte-like PLA microspheres demonstrated narrow size distribution and uniform 
morphology. As the PLA concentration increased to 2 wt%, two kinds of microspheres, PLA 




microspheres (Figure 5.2b), beaded microspheres (Figure 5.2c) with a certain amount of 
concomitant nanofibre were fabricated. It indicates that higher polymer concentrations tend to 
form fibres.  
 
 
Figure 5.2  Scanning electron microscope images of electrosprayed PLA microfibres with 
two kinds of PLA microspheres, b) microspheres and c) beaded microspheres. 
 
On further increase of PLA concentration to 4.5 wt%, PLA beaded microfibres appeared 
(Figure 5.3 a,b). This phenomenon agrees with former chapters’ studies, and there is a 
transition stage between spherical structures and fibrous structures. Finally, when the 
polymer concentration was eventually increased to 9.6 wt%, the microfibres were formed, as 











Figure 5.3  Scanning electron microscope images of electrosprayed PLA a,b) beaded 
microfibre and c,d) microfibres. 
 
Both PLA and PLGA have been widely accepted for use in medical devices due to their 
excellent biocompatibility. The PLA and PLGA materials also exhibit low toxicity and 
immunogenicity, as well as well-defined biodegradation. Compared with PLGA, the absence 
of glycolic acid segments makes PLA more hydrophobic and results in longer degradation 
kinetics. Therefore, electrospun PLA was chosen rather than PLGA as a fibrous carrier in the 










Figure 5.4  Scanning electron microscope images of electrosprayed a,b) PLGA flattened 
microspheres, c,d) PLGA microspheres. 
 
Firstly, erythrocyte-like PLA microspheres were used as a spherical component. 
Unfortunately, it was found that the erythrocyte-like PLA microspheres could not tightly 
incorporate into the PLA microfibres matrices. Part of the erythrocyte-like PLA microspheres 
even dropped out from the composites matrices when it was incubating in the release medium 
aCSF. Then, as discussed in former chapters, flattened PLGA microspheres (3.5 wt%, Figure 
5.4 a,b) and PLGA microspheres (4.5 wt%, Figure 5.4 c,d) were also tried as the spherical 
component. The outcome was that the Flattened PLGA microspheres could be firmly 
attached to the PLA microfibres. The mechanism and more detailed information are 
20 µm 2 µm





discussed and given below. All microcapsules with various polymers, structure, and their 
respective fabrication conditions are summarized in Table 5.2. 
 







PLA 0.75 10 Erythrocyte-like 
microspheres 
PLA 2.0 10 Microspheres, beaded 
spheres, and fibres 
PLA 4.5 21 Beaded microfibres 
PLA 9.6 21 Microfibres 
PLGA 3.5 10 Microspheres 











Figure 5.5  Schematic of the fabrication process of dual drug delivery composite matrices by 
using combinatorial electrospinning and electrospraying; the stable Taylor core of PLA 
solution (containing phenytoin or lacosamide) tend to form microfibres, and the unstable 
Taylor core of PLGA solution (containing lacosamide or dexamethasone) tend to form 
microspheres. 
 
Figure 5.5 shows the schematic fabrication process of composite matrices as dual drug 
delivery systems. In order to minimize the charge effect between electrospinning and 






































mandrel, and PLA microfibres were electrospun on the other side, to generate the composite 
matrices.  
 
Different from electrospinning, the Taylor core (as shown in Figure 5.5) is unstable in the 
electrospraying process, and the liquid jet is destabilized due to varicose instability, and 
hence fine droplets were formed [24].  
 
Figure 5.6 Scanning electron microscope images of PLA phenytoin microfibres/ PLGA 








While the drops move from the needle tip to the rotating mandrel, rapid solvent evaporation 
and polymer diffusion occurs. This leads to the formation of spherical microparticles. When a 
low concentration of PLGA, such as 3.5 wt%, was used in this work, flattened microspheres 
were formed. This is due to incomplete solvent evaporation, and, therefore, the 
electrosprayed microcapsules are still partially dissolved when they reach the surface of the 
PLA microfibres. Before hitting the surface of the PLA microfibres, there is still a small 
amount of residual solvent in the PLGA microspheres; which makes the microspheres deform 
and flatten, and firmly attaching to the microfibre to form a conglutinated stable composite 
matrix structure [23]. When PLGA microspheres were electrosprayed in combination with 
PLA microfibres, a relatively uniform distribution within the microfibres was observed 
(Figure 5.6 and 5.7). This results in the formation of composite matrices with randomly 
deposited microspheres and microfibres.  
 
As a proof of combined therapeutic conception, two composite matrices were fabricated. 
They contain different drugs: PLA phenytoin microfibres/PLGA lacosamide microspheres 
composite matrices and PLA lacosamide microfibres/PLGA dexamethasone microspheres 
composite matrices. In order to tailor the dosage ratio of two drugs in each composite matrix, 
the quantity of PLGA microspheres was roughly controlled by simply varying the duration of 
the electrospinning and the electrospraying. As a result, PLA phenytoin microfibres were 
incorporated with fewer PLGA lacosamide microspheres, and PLA lacosamide microfibres 
were incorporated with more PLGA dexamethasone microspheres. The SEM images (Figure 








Figure 5.7  Scanning electron microscope images of PLA lacosamide microfibres/ PLGA 
















5.3.3 Thermal properties of composite matrices 
Thermogravimetric analysis (TGA) curves of the PLA microfibres, PLA-phenytoin 
microfibres/PLGA-lacosamide microspheres composites, PLA-lacosamide 
microfibres/PLGA-dexamethasone microspheres composites and PLGA microspheres are 














The initial weight loss found up to 120 
o
C is probably attributable to the physical loss of 
moisture. It indicates that the weight loss at this stage is not related to polymer thermal 
Figure 5.8 Thermogravimetric analyses (TGA) results of the as-fabricated 
PLGA microspheres, PLA microfibres matrices and composite matrices 
which contain drugs. 
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and this is attributed to the decomposition of the polymer chains [25]. Without the drug, both 
PLA microfibres and PLGA microspheres showed nearly zero residues. However, the 
composite matrices demonstrated higher carbon residues. This may be ascribed to the 
aromatic ring structure of the model drugs. In addition, evidence for drug encapsulation is 
also afforded by these TGA plots which are shown above. 
 
5.3.4 Mechanical properties of the composite matrices 
For drug delivery systems, mechanical properties are important since deformation or fracture 
in the implanted device will significantly affect the drug release kinetics [26].  
 
Table 5.3 Mechanical properties of electrospun PLA microfibre and the composite matrices. 




Strain at break 
(%) 

























The typical stress-strain curves acquired from PLA microfibres matrices, PLA phenytoin 
microfibres/PLGA lacosamide microspheres composite matrices, and PLA lacosamide 
microfibres/PLGA dexamethasone microspheres composite matrices are shown in Figure 5.9 












All PLA microfibres matrices and composite matrices demonstrated high tensile strength, as 
well as high tensile modulus. The favourable mechanical properties can be ascribed to the 
high molecular orientation along the PLA microfibres axes [27]. During the formation of 
microfibres, the liquid jet undergoes a whipping or bending motion process, which is very 
fast and leads to the rapid drawing of the molecular chain among the microfibres. The tensile 
Figure 5.9 Typical tensile stress-strain results of as-fabricated PLA microfibres 
matrices and composite matrices which contain drugs. 





















 PLA Fiber 
 PLA Phenytoin-PLGA Lacosamide
 PLA Lacosamide-PLGA Dexamethasone
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strength of the PLA fibres matrices is 4.6±0.81 MPa, slightly increased to 6.0±0.46 MPa for 
PLA phenytoin/PLGA lacosamide composite matrices (fibres with fewer spheres), then 
slightly decreased to 2.8±0.21 MPa for PLA lacosamide/PLGA dexamethasone composite 
matrices (fibres with more spheres). While, the modulus initially increased from 97±7.6 MPa 
to 172±42 MPa, and then decreased to 66±13 MPa.  With increasing numbers, microspheres 
cannot be distributed uniformly. Instead, they formed small partial spherical accumulations, 
and these accumulations became structural defects in the composite matrices. When the 
composite matrices are under tensile testing, the defects made them fracture easily [28, 
29].5.3.5 In vitro drug release study and mathematical simulation 
 
 






5.3.5 In vitro drug release study and mathematical simulation 
Drug encapsulation efficiency is an important index for drug delivery systems, especially for 
rare and expensive drugs. A suitable microencapsulation technique should result in high 
encapsulation efficiency[30]. Drug encapsulation efficiency testing was conducted by using 
an extraction method. As shown in Figure 5.10, all microfibres and microspheres 
demonstrated high drug encapsulation efficiency. They were 97.2±3.7% for PLA phenytoin 
microfibres, 90.6±10.3% for PLGA lacosamide microspheres, 93.5±4.6% for PLA 
lacosamide microfibres, 91.0± 7.2% for PLGA dexamethasone microspheres. The total 
encapsulation content of two kinds of drugs in each microsphere was also detected by the 
extraction method. Composite matrices with more microspheres contained fivefold higher 





Figure 5.11 Cumulative release of each drug from PLA phenytoin microfibres-PLGA 
lacosamide microspheres composite matrices. 
 
In general, drugs which were encapsulated in microspheres were released faster than those 
encapsulated in microfibres. PLGA lacosamide microspheres exhibited rapid release, ~62% 
of total lacosamide within 24 hours, and ~96% within 220 hours. While PLA phenytoin 
microfibres just released ~16% of total phenytoin within 24 hours, followed by a slower 
release of up to 45% within 220 hours. The release rates of PLA lacosamide microfibres and 
PLGA dexamethasone microspheres were not so obviously different, but it still exhibited 
independent release characteristics. The entire release rates were with an initial burst, then 
with a long slower period. As the composite matrices were placed in aCSF medium, water 
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rapidly penetrated into the exposed surface of microspheres and microfibres, and the drugs 
trapped within a thin surface layer were quickly released. Subsequently, it took a longer time 
for water to diffuse in and the drugs to diffuse out, thus limiting the later drug release rates 
[31].  
 
Figure 5.12 Cumulative release of each drug from PLA lacosamide microfibre/PLGA 
dexamethasone microspheres composite matrices. 
 
As shown in in vitro drug release testing, the release profiles of the drugs vary with the 
morphology and shape dimension of the microfibres and microspheres. In order to evaluate 
the effects of morphology, shape dimension, and develop a capability for predicting the 
kinetics of drugs release of the microfibres and microspheres, a theoretical analysis of time-
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dependent diffusion with an initially uniform drug concentration was performed. For 
mathematical simulation of microspheres and microfibres, a drug release profile is obtained 
by solving Fick’s second law as described in chapter 3. The fraction of the initial drug 
loading released from the microcapsules (Mt/M∞) at any time (t) can be expressed by 














                              (3.1) 
 
 
Figure 5.13 Dimensional statistical analysis results of diameters including PLA phenytoin 




The diameters of the microfibres and microspheres are assessed by analyzing the SEM 
images, and the results are shown in Figure 5.13. The diameters are 1.19±0.34 µm for PLA 
phenytoin microfibres, 5.57±1.15 µm for PLGA lacosamide microspheres, 1.22±0.37 µm for 
PLA lacosamide microfibres, and 4.63± 0.68 µm for PLGA dexamethasone microspheres.  
 
 
Figure 5.14 Diameters distribution of PLA phenytoin microfibres, PLGA lacosamide 
microspheres, PLA lacosamide microfibre, and PLGA dexamethasone microspheres. 
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Moreover, as shown in Figure 5.14, all the microfibres and microspheres of the composite 
matrices exhibit narrow size distribution and uniform morphology. The mathematical 
modelling study is based on the equation (3.1) and using MATLAB Curve Fitting Toolbox.  
 
 
Figure 5.15 Mathematical modelling of drug release of PLA penytoin fibres and PLGA 
lacosamide spheres (solid curves: theory fitting results, symbols and standard deviations: 
experimental sampling points). 
 
The effective diffusivities of drugs are used as a least-squares fitting parameter, as shown in 
Figure 5.15 and Figure 5.16, the theoretical predictions from the mathematical modelling 
are in agreement with the experimental cumulative release data . It indicates that drug release 
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from the microfibres and microspheres of these composite matrices can be satisfactorily 



















/min for PLGA dexamethasone microspheres. This is the reason why microspheres 
exhibit significantly faster release kinetics than those of microfibres. 
 










Overall, this study considered the use of a combinatorial electrospinning and electrospraying 
system to fabricate PLA microfibres/ PLGA microspheres composite matrices for dual drug 
delivery. The as-fabricated composite matrices showed favorable thermal and mechanical 
properties. And the microfibres and microspheres of the composite matrices demonstrated 
narrow size distribution, uniform morphology, and high efficiency of drug encapsulation. 
Independently controlled release behaviours are achieved in these dual drug delivery 
composite matrices. And the dosage ratio of different drugs in composite matrices could be 
tailored by simply varying the electrospinning and electrospraying time. The release profiles 
are fit well with the mathematical simulation model. This result indicates that the release 
kinetics is predictable. A similar strategy could be introduced to other dual drug release 
systems to provide a wide range of biomedical applications such as growth factor for cell 
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6. CHAPTER 6: CONDUCTING AND 
BIODEGRADABLE POLYMERS 
COMBINED 3-DIMENSIONAL 











Conducting polymers (CPs) have received considerable interest in recent decades for their 
unique and tunable physical and chemical properties [1-5]. Their attractive electrical, optical, 
mechanical, and interfacial properties are derived from their conjugated π-electron system. 
CPs have been investigated for numerous biomedical applications, including electrically 
controlled release [6-9], tissue engineering [10, 11] [12], neural prosthesis [13, 14], bio-
sensors [15], and bio-actuators [16, 17] et al. . In these applications, polypyrrole (PPy) and 
poly(3,4-ethylenedioxythiophene) (PEDOT) are popular candidates because of their chemical 
stability, superior conductivity, and biocompatibility. Moreover, they can be readily prepared 
by chemical or electrochemical means [4]. During the course of preparation, appropriately 
sized biomolecules and drugs can be incorporated into the polymer matrices. In addition, 
these polymers exhibit low electrochemical impedance, and this facilitates controlled release 
of the entrapped bioactive molecules via electrical stimulation [6].  
 
To date, most of the CPs based electrical stimuli drug delivery systems have been limited to 
2D configurations [7, 18]. However, many clinical applications in drug delivery require more 
sophisticated structures in three dimensions, in addition to biocompatibility and excellent 
mechanical properties[19]. It is a huge challenge to progress towards 3D electroactive 
delivery systems with well-controlled internal structures, because of their poor processability 
(poor solubility in solvents and inability to directly melt process) of CPs. What’s more, free 
standing films of CPs tend to be brittle，inflexible and have poor conductivity. To overcome 
these drawbacks, attention has been given to developing CP coatings on prefabricated 3D 




Recently, additive manufacturing, also known as 3D printing, has shown great promise as a 
novel technology for fabrication of 3D constructs with sophisticated internal structures. 3D 
printing involves layer-by-layer deposition of materials, which is controlled digitally, and 
thus can deliver complex, personalized and on-demand products. More recently, 3D printing 
has attracted increasing interest in pharmaceutical manufacturing. Progress has resulted in the 
Food and Drug Administration (FDA) approval of 3D printed drug products from August 
2015 [20, 21].  
Selective laser melting (SLM) is a popular 3D printing process to fabricate metal products 
[22]. During the SLM process, the laser beam selectively melts successive layers of metallic 
powder. Upon irradiation, the powder melts and forms a liquid pool. Then, it solidifies 
quickly to form 3D structures according to a 3D Computer-aided design (CAD) volume 
model. Being able to design and create geometrically complex metallic objects, it could be 
interesting for the application of SLM products in CPs drug delivery systems. 
 
In previous chapters, a set of biodegradable microcapsules including microspheres and 
microfibres have been developed. Moreover, composite membranes composed of these 
microcapsules also have been fabricated as dual drug delivery systems that can be used for 
combination therapy. In this chapter, an attempt at the application of these biodegradable 
microcapsules in 3D printed electrodes is considered. The attempt also aims to explore the 
way to continue development of dual drug delivery systems for combination therapy. 
Fortunately, the 3D printed electrodes based on the interdigitated structures offer the 





This chapter aims to demonstrate a new 3D system for the controlled release of antiepileptic 
drugs by electrical stimulation. 3D printed (selective laser melting) interdigitated Ti6Al4V 
electrodes serve as the structural support for the electropolymerized outer layer of 
polypyrrole (PPy). Fosphenytoin is an anti-epilepsy prodrug (AED) and is used as the dopant 
for the preparation of the 3D PPy coating. The release of fosphenytoin in artificial 
cerebrospinal fluid (aCSF) from the 3D drug delivery system is controlled by switching the 
redox state of PPy. Moreover, combined with biodegradable microspheres which contain 
dexamethasone (independently coated on the electrode), two interdigitated electrodes can 
serve as a multi-functional drug delivery system. The electrical conductivity, biocompatibility 
and tuneable release properties of the 3D printed drug delivery system can also lead to 





Ti-6Al-4V powder was from TLS Technik Spezialpulver. Pyrrole monomer was from Merck 
and was freshly distilled before use. Poly(D,L lactic-co-glycolic acid) (PLGA) (Mw ~ 60,000 
Da, molar ratio of lactide to glycolide, 75 to 25) was purchased from Purac, Singapore. 
Fosphenytoin and dexamethasone were purchased from Sigma-Aldrich, and used as received. 
All the others chemicals and reagents were purchased from Sigma-Aldrich and used as 




6.2.2 3D printing of interdigitated electrodes 
The 3D interdigitated electrodes were designed using SolidWorks modelling software. After 
that, the electrodes were printed by using a Realizer SLM50 metal printer (Germany). The 
printer is based on the additive manufacturing technology which is called Selective Laser 
Melting (SLM). Before printing, the printer’s chamber is evacuated and then filled with an 
inert argon atmosphere. The high-powered laser beam of the printer focused on a bed of fine 
Ti-6Al-4V powder. The laser selectively fuses the particles in a layer-by-layer fashion. All 
untouched powder remains as it is and becomes a support structure for the electrode.  
 
6.2.3 3D coating of fosphenytoin loaded conducting film 
Milli-Q water and ethanol were used to clean the 3D printed Ti alloy electrodes. A solution 
containing 0.2 M pyrrole monomer and 0.02 M fosphenytoin was prepared in Milli-Q water. 
Electrochemical polymerization was carried out using a CHI 600 (CH Instruments) at a 
constant potential of 0.8 V for 20 mins at room temperature. The applied reference electrode 
was silver/silver chloride reference electrode, and the counter electrode was stainless steel 
mesh. The electrodes were rinsed with a Milli-Q water/ethanol mixture in order to remove 
any residual fos-phenytoin, pyrrole, and oligomers on the surface. Then, the electrodes were 
dried in a vacuum oven at room temperature for 24 hours. 
 
6.2.4 Electrospray coating of PLGA dexamethasone microspheres on the 3D electrodes 
PLGA was dissolved in chloroform at 4 wt.%; subsequently, dexamethasone was added into 
the PLGA solution to obtain the electrospraying solution (PLGA:dexamethasone, 10:1). After 
encapsulation efficiency testing, a drug loading of 9.35 % was achieved. The solution was 
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held in a syringe with a stainless steel needle having an orifice of 0.34 mm. The needle was 
electrically connected to a positive high voltage power supply of NANON-01A electrojetting 
systems (MECC Co. Ltd, Japan). Electrospraying was carried out in the electrojetting 
systems’ chamber at room temperature. During the electrospraying process, a positive high 
voltage of 10 kV was applied to the needle, and the solution flow rate of 0.5 mL/h was 
maintained by using a syringe pump. Electrosprayed PLGA/dexamethasone microspheres 
were collected on the surface of the 3D printed electrodes. After that, the electrodes were 
held at room temperature for 48 hours in a fume hood to allow completion of the residual 
solvent evaporation. 
 
6.2.5 Scanning electron microscope  
The morphology characterization was performed by JEOL JSM-7500FA scanning electron 
microscope (SEM) with field emission gun (FEG). For conductive Ti alloy electrodes and 
polypyrrole, SEM testing was conducted directly without sputter-coating. Non-conductive 
PLGA microspheres were sputter-coated with 20 nm gold before SEM testing.  
 
6.2.6 Electrochemical measurements 
Electrochemical impedance spectroscopy (EIS) was measured using a Gamry EIS 3000 
TM
 
system with Gamry framework software using a three-electrode system. The frequency range 
was from 0.1 Hz to 100 kHz, and the AC perturbation was 5 mV at open circuit potential. 
Cyclic voltammetry (CV) was carried out in a three-electrode system with a Pt counter 
electrode and Ag/AgCl reference electrode by using a CHI 600 (CH Instruments) apparatus. 
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A scan rate of 100 mV/s was used, and the potential applied was swept between -1.0 and 0.5 
V.  
 
6.2.7 In vitro electrically controlled drug release 
Electrically controlled drug release experiments were carried out in a three-electrode 
electrochemical cell using artificial cerebrospinal fluid (aCSF) as the release medium. A 
square wave, biphasic voltage stimulation was used for electrically stimulating drug release. 
The applied negative potentials were -1 V, -0.5 V, and -0.25 V, respectively, and the positive 
potential was 0.5 V.  Each square wave (cycle) of the electrical stimulation was a 50% duty 
cycle; 5 seconds of negative potential and 5 seconds of positive potential.  Every 30 cycles 
(or more) of square wave electrical stimulation, the release medium was collected and 
replenished with fresh aCSF. For comparison, passive drug release study was also conducted 
without electrical stimulation.  
 
6.2.8 PLGA microsphere diametric statistics and drug release study 
Diametric statistics was conducted by analysis of the high magnification SEM micrographs 
using the imaging software, Leica Application Suite. Drug release study was conducted in 
aCSF. The electrodes with PLGA microsphere were directly immersed in a certain amount of 
aCSF. All the samples were incubated in a shaking water bath at a constant temperature of 37 
o
C. The release media was replaced with the same amount of fresh aCSF periodically. An 
extraction method was used to evaluate the drug encapsulation efficiency of the microsphere 
as described in our previous work [24]. In order to predict the release profile of 
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dexamethasone from the electrosprayed coating, the mathematical analysis was conducted 
based on a time-dependent diffusion model and using MATLAB Curve Fitting Toolbox.  
 
6.2.9 Determination of the amount of released fosphenytoin and dexamethasone 
Both the amounts of fosphenytoin and dexamethasone were determined by HPLC, using an 
Agilent 1260 Infinity HPLC system. The analytical column was Atlantis
®
 T3 C18 column (5 
µm, 250 mm × 4.60 mm). For fos-phenytoin testing, the mobile phase consisted of 35% (v/v) 
methanol and 65% (v/v) of Milli-Q water. The pH was adjusted to ~3.8 with orthophosphoric 
acid; the flow rate was 1 mL/min; the wavelength of UV was 210 nm. For dexamethasone 
testing, the mobile phase consisted of Milli-Q water and acetonitrile (35:65, v/v) with 0.1 % 
trifluoroacetic acid (v/v); the flow rate was 1.0 mL/min; UV detection wavelength was set at 
242 nm. The amounts of the released drug were calculated according to a pre-established 
calibration curve. 
 
6.3 Results and Discussion 
 
6.3.1 Fabrication and assembly of the interdigitated 3D electrodes 
The 3D interdigitated electrodes were designed and printed by using selective laser melting 
(SLM). As shown in Figure 6.1a, electropolymerization was used to deposit a film of PPy 
and fosphenytoin on the surface of the 3D electrodes. In the solution containing dopant, the 
pyrrole monomers became electrically oxidized and underwent polymerization. During 
polymerization, the polymer backbone was positively charged, and the anionic dopant 
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molecule was incorporated to maintain charge neutrality [25].  In this study, the dopant was 
fosphenytoin, which is a water-soluble phenytoin prodrug and can be converted into the 
active form, namely phenytoin. It is often used in the acute treatment of epilepsy [26].  
 
Figure 6.1 Schematic illustration of the fabrication procedures of a) electropolymerization of 
PPy fos-phenytoin on the 3D printed electrodes; b) electrosprayed PLGA microspheres 
coating on 3D electrodes. 
 
In order to incorporate the non-anionic drug into the printed 3D electrodes drug delivery 
system, PLGA microspheres were fabricated by electrospray as drug carrier and coated on the 
surface of the electrodes (Figure 6.1b). Dexamethasone was used as a model drug because of 
its wide application in anti-inflammatory uses and is an immunosuppressant [27]. Our 
electrodes drug delivery system is aimed at local implantation for treatment of epilepsy, 
therefore, inflammation and immune response may be inevitable [28]. Dexamethasone loaded 







dexamethasone chloroform solution and coating on the surface of the posts of the 3D 
electrode. Several parameters including the concentration of PLGA, solution feed rate, and 
applied voltage were tested in order to obtain appropriate microspheres. It was observed that 
the as-fabricated microspheres could attach firmly, not just with each other, but also on the 
surface of the electrodes. This is probably due to incomplete solvent evaporation when the 
PLGA microspheres were reaching onto the electrode collector  [29].  
 
 
Figure 6.2 Schematic of fabrication procedures of a) assembly process of two interdigitated 
PPy fos-phenytoin coated electrodes; b) assembly process of interdigitated PPy fos-phenytoin 
coated electrode and electrospray PLGA microspheres coated 3D electrode on insulated base. 
 
Figure 6.2 shows the interdigitated electrodes device assembly process. After 
electropolymerization or electrospraying, two halves of the interdigitated electrodes were 
b
Assembly on insulated base 




assembled on their insulated bases and served as alternating working and counter electrodes 
when subject to biphasic square wave electrical stimulation. This interdigitated structure 
combined them together and afforded more materials loading within the same dimension 
[30]. Furthermore, the size of the posts in these electrodes could be reduced to further 
increase the total materials loading. What’s more, the size of the 3D electrode drug release 
device could be adjusted, depending on the particular application. 
 
6.3.2 Scanning Electron Microscopy 
The electrodes used in this study were 1 cm by 1cm by 1 cm and contain 54 posts. Each post 
had a ~500 µm diameter and 8 mm height. The High magnification SEM image shows that 





Figure 6.3 Scanning Electron Microscopy images of a,b) a whole 3D electrode and 
individual post; c,d) high magnification of the bare 3D electrode. 
This provides an enhanced surface area for the electropolymerization. After 
electropolymerization, the smooth metal surface (Figure 6.3c,d) is covered by a layer of PPy 








Figure 6.4 Scanning Electron Microscopy images of the PPy-fosphenytoin coating. 
 
The dexamethasone loaded PLGA microspheres are coated on another electrode rather than 
on the same electrode with PPy-fosphenytoin. This aims to minimise the interaction of the 
drug release. As shown in Figure 6.5, it is noted that there are many gaps between the 







release media. The release media penetrates into the microsphere coating then contacts the 
surface of the electrode.  
 
Figure 6.5 Scanning Electron Microscopy images of electrosprayed PLGA dexamethasone 








6.3.3 Electrochemical impedance spectroscopy 
The electrical properties of the 3D electrodes were tested using electrochemical impedance 
spectroscopy (EIS) and cyclic voltammetry. EIS was used to assess the conductivity of the 
bare electrode, PPy coated electrode and PLGA microsphere-coated electrode over the 





















































 Bare 3D electrode
 PLGA 3D electrode
 PPy 3D electrode
Figure 6.6 The electrochemical testing results of Impedance spectra for bare 
3D electrode, PLGA dexamethasone microspheres coated 3D electrode, and 
PPy fos-phenytoin modified 3D electrode. 
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The impedance of the bare electrode was from ~5.34 kΩ to ~18 Ω. After PLGA microspheres 
were coated on the surface, the impedance across all frequencies was increased, from ~6.28 
kΩ to ~29 Ω. However, the impedance initially significantly decreased and then slowly 
decreased after deposition of the PPy, from ~360 Ω to 16 Ω. In the study here, the impedance 
at 1 kHz is particularly important. Since it corresponds to the characteristic frequency of 
neuronal action potentials [6, 31]. For the bare electrode, the impedance at 1 kHz was ~16 Ω; 
it was increased to ~36 Ω for the PLGA microsphere-coated electrode but was decreased to 
~12 Ω for the PPy-coated electrode. These indicate that the PLGA microspheres diminish the 
capacitance, while PPy coating improves the capacitance of the electrode interface. However, 
the modifications are not dramatic at this frequency. 
 
6.3.4 Cyclic Voltammetry 
Cyclic Voltammetry (CV) provides information about the intrinsic redox behaviour of the 
electrode materials (Figure 6.7). CV analysis results showed that both the bare electrode and 
PLGA microsphere-coated electrode demonstrated negligible charge-storage capacity 
compared with the PPy-coated electrode. The charge-storage capacity was calculated from 
the integrated area of the CV curves. The CV curve of the PPy-coated electrode exhibits a 
reduction peak at -0.71 V and an oxidation peak at -0.06 V. The reduction peak due to the 
anionic fos-phenytoin molecules leave the PPy film as a consequence of the negative 
potential sweeping. And the oxidation peak is related to re-doping of small ions in the testing 
media [7]. The huge reduction peak of the PPy coated electrode indicates a large amount of 
drug leaving the PPy film [32]. Also, with a lower impedance of the PPy coated electrode, 
more current will pass through the PPy film under a particular voltage pulse. It also shows 















6.3.5 Electrically controlled release of fosphenytoin 
The electrically controlled release performance of the PPy coated 3D electrodes was studied 
in aCSF solution by applying voltage pulses. The amount of released fosphenytoin was 
determined by HPLC. The electrically triggered release possibly involves a synergistic 
process of electrochemical reduction/oxidation and electrically driven movement of charged 
molecules. In this study, anionic fos-phenytoin molecules were incorporated into the PPy 
coating [6, 32, 33]. When the PPy coating is electrochemically reduced, the fosphenytoin 
molecules will be released. The release of the drug is associated with the change of the 
















 Bare 3D electrode
 PLGA 3D electrode
 PPy 3D electrode
Figure 6.7 Cyclic voltammograms of the bare 3D electrode, PLGA dexamethasone 
microspheres coated 3D electrode, and PPy fos-phenytoin modified 3D electrode. 
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overall net charge along the PPy backbone in the oxidized form. The drug released during the 
















To evaluate the maximum amount of fosphenytoin released from the PPy coating, an 
aggressive, biphasic voltage pulse (-1 V for 5s, followed by 0 V for 5s) was used as 
Figure 6.8 Electrically controlled fos-phenytoin release: a) cumulative release profile 
using repeated square wave, biphasic voltage stimulation (-1 V for 5s, followed by 0 
V for 5s) to determine the total available drug. 
































stimulation until no obvious drug release could be detected (~1400 stimulations). The drug 
release curve in Figure 6.8 shows a plateau after ~750 stimulations, after which no 















Upon milder electrical stimulation (-0.5 V for 5s, followed by 0.5 V for 5s), a near-linear 
drug release profile is obtained (Figure 6.9). Without stimulation, there was no detection of 
any significant amounts of drug eluted from the 3D electrode.  This is consistent with others’ 
Figure 6.9 Cumulative release profiles in response to milder electrical square 
wave, biphasic voltage stimulation (-0.5 V for 5s, followed by 0.5 V for 5s), and 
without electrical stimulation. 






























observation, which suggests that this system under consideration is capable of true 
electrically controlled release property [32]. In order to demonstrate the flexibility in dosage 
control, further drug release studies under different voltage (x) biphasic stimulations (x V for 
5s, followed by 0.5 V for 5s) up to 120, where the negative phase (x) was varied from -0.25 
to -1 V, the positive phase was 0.5 V were performed. The released amount of drug increased 














Figure 6.10 Release amount under 120 cycles of different square wave, biphasic voltage 






















Negative phase potential of square wave, 
biphasic voltage stimulation (V)
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Compared with the single half-electrode, the cumulative amount of released drug from two 
interdigitated electrodes was 276±25.3 µg , an increase of 82 % (after 1200 cycles, Figure 
6.11). This highlights the advantage of interdigitated electrodes in the application of 















Figure 6.11 Comparison of the release amount from a single 3D electrode with 
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As shown in Figure 6.12, after 1200 cycles of electrical stimulations (pulsed waveform; -0.5 
V for 5s, followed by 0.5 V for 5s), no obvious delamination or breakdown was observed on 
the surface of the PPy coating, indicating good stability.  
 
 
Figure 6.12 SEM images of the PPy fos-phenytoin coating after 1200 cycles of electrical 
square wave, biphasic voltage stimulation (-0.5 V for 5s, followed by 0.5 V for 5s), no 







6.3.6 Drug release study of 3D electrode coated with PLGA/dexamethasone 
microspheres coating 
The drug encapsulation efficiency and drug release were first investigated by using an 
extraction method as previously reported [34]. For effective drug action, improving the drug 
encapsulation efficiency is critical in drug carrier research [35].  
 
The PLGA microspheres coating exhibit excellent drug encapsulation efficiency as high as 
93.5±5.1 %. The ultra-high drug encapsulation efficiency can be attributed to fast 
solidification rate and minimum drug loss during the PLGA microspheres coating fabrication 
process. Since the dexamethasone is directly encapsulated in PLGA by electrospraying, the 
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Figure 6.13 Cumulative release of PLGA dexamethasone microspheres coating in 




The in vitro release profile of dexamethasone from the electrospray PLGA microspheres 
coating is shown in Figure 6.13. It shows an initial burst, followed by a long period of 
gradual slowing release over nearly two weeks for the PLGA microspheres coating. Besides 
by diffusion through the polymer barrier, the dexamethasone release from the PLGA 
microspheres coating also occurs by erosion of the microspheres, due to the hydrolytic 
degradation of the ester linkages. This degradation leads to formation of interconnecting 
pores and channels within the microspheres in the coating which would increase diffusion of 
the dexamethasone into the aCSF solution. The rapid initial release was probably due to the 
drug aggregation close to the surface of the PLGA microspheres in the coating [36]. Due to 
the hydrophobic characteristics of dexamethasone, there is a tendency for it to migrate to the 
surface during electrospraying. Whereas the latter gradual slow release maybe ascribed to 
diffusion of the drug within the core of the PLGA microspheres coating. 
 
For PPy, drug release can be switched on/off and accurately controlled by electrical 
stimulation, while for PLGA microspheres coating, the release of dexamethasone is passive 
and Fickian diffusion related. Previous studies have elucidated the complex phenomena that 
are involved in the control of drug release from PLGA microspheres [24, 38, 39]. It has been 
identified that the crucial drug release rate was controlled by a diffusion mechanism.  For the 
PLGA microspheres coating, the diffusion controlled release rate decreases with increasing 
size of the microspheres coating. Size increase leads to slower drug release since the drug has 
a further distance to diffuse to the surface of the microsphere. It’s important to apply a 
mathematical model which takes into consideration the size and shape matters of the PLGA 




The mathematical model assumes uniform initial drug distribution in the microspheres and 
constant drug diffusion coefficients. Based on this assumption and Fick’s second law, the 













                             (6.1) 
Where M𝑡 is the amount of drug release at time 𝑡, 𝑀∞ is the total amount drug release, 𝑑 is 
the diameters of the microspheres in coating, 𝐷𝑒  is the effective diffusivity of the drug 











Figure 6.14 Diameters distribution of the dexamethasone PLGA microspheres. 




















The diameters ( 𝑑) were obtained by analysis of the SEM images of the PLGA microspheres 
coating. The diameters are 3.97±0.44 µm, and the diameters distribution is shown in Figure 
6.14. It shows that the as-fabricated microspheres coating have uniform morphology with a 















The fitting method was based on the minimization of the differences between experimental 
and theoretical results (least squares fitting method). The fitted results agree well with the 
























)  PLGA microsphere drug release
Time (h)
 PLGA microsphere Fitting release
Figure 6.15 Comparison of the mathematical modelling results with the 
experimental drug release profiles of electrospray PLGA dexamethasone 
microspheres coating.  
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experimental drug release rate (Figure 6.15). It’s consistent with previous studies, and the 
drug release mechanism of the PLGA microspheres can be described as a time-dependent 





/min, which is within the values range of hydrophobic drugs in a PLGA matrix [40].  
 
 
Figure 6.16 SEM images of PLGA dexamethasone microspheres coating after more than 








We also conducted SEM observations on the PLGA microspheres coating after more than 
three months of release. Figure 6.16 shows that the PLGA retained its spherical structure. 
This confirms that the breakdown of the polymeric network does not occur during the whole 
drug release period. Thus, it does not contribute to the control of the release process. 
 
6.4 Conclusion 
In summary, this work developed 3D drug delivery systems based on 3D printed electrodes. 
After electropolymerization of a layer of PPy fos-phenytoin coating, the 3D electrodes 
showed electrically controlled property, sustained near-linear release, flexible dosage control, 
and super stability. The electrosprayed PLGA dexamethasone microspheres coated on the 3D 
electrodes demonstrated uniform morphology and theoretically predictable release properties. 
The combination of conducting and biodegradable polymers by these two interdigitated 
electrodes can serve as multi-functional drug delivery systems. The electrical conductivity, 
biocompatibility and controllable release of this 3D printed drug delivery system can lead to 
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7.1 General Conclusion 
The main aim of this study was to develop biocompatible controlled drug delivery systems 
for treatment of central nervous system disorders such as epilepsy. Biodegradable polymer 
and conducting polymer were used as carriers. The US Food and Drug Administration (FDA) 
approved lacosamide, phenytoin and dexamethasone are used as model drugs. Electrojetting 
and electropolymerization are used as fabrication methods.  
 
The preparation and characterization of microcapsules including flattened microspheres, 
microspheres, and microfibres are described in chapter 3. Electrojetting technology 
(electrospraying and electrospinning) were used to fabricate these microcapsules containing 
the anti-epilepsy drug, lacosamide. The SEM images and their statistical analysis results 
showed uniform morphology and a narrow size distribution of the microcapsules. The drug 
release study demonstrated high drug encapsulation efficiency, and that their drug release 
profiles are dependent on the shape and size of the microcapsules. The mathematical 
modelling studies demonstrated that all drug release profiles could be predicted, with a good 
agreement between the modelling and experimental results. Human neural stem cell culture 
results indicated the neuro-cytocompatibility of the microcapsules. It was confirmed by the 
cell attachment and viability during extended cell culture with the microcapsules. These 
findings broadly support the utility and efficacy of the local drug delivery systems for treating 




After successful fabrication of the neuro-compatible microcapsules, the development of core-
shell structural microcapsules using the same biodegradable polymer was investigated in 
chapter 4. A series of core-shell microcapsules were prepared via novel core-shell 
electrojetting, where a more hydrophobic polymer shell acts as a barrier component to control 
the rate of drug release from the polymeric core. By adjusting the applied voltage and the 
core and shell solution compositions, different kinds of microcapsules were successfully 
obtained, including core/-shell microflakes, flattened microspheres and microspheres, 
microspheres/fibres, microbeads/fibres, and microfibres. The release profile varies with the 
morphologies and shape of the core-shell microcapsules and thus can be readily controlled 
over long periods of time. 
 
Many central nervous system disorders in clinical situations require more than mono drug 
release. For example, combination therapy with drugs of different therapeutic effects 
provides an effective strategy in the treatment of epilepsy. Electrospun microfibres and 
electrosprayed microspheres composite membranes were prepared as dual drug delivery 
systems in chapter 5. These composite membranes were loaded with two drugs, one in the 
biodegradable microspheres and the other in the microfibres. The microspheres and 
microfibres could form stable composite structures. Thermogravimetric analysis and tensile 
testing results indicated favourable thermal and mechanical properties. Independently 
controlled release behaviours are achieved in these dual drug delivery composite membranes.  
 
In chapter 6, 3D printed interdigitated electrodes were used as drug delivery systems by a 
combination of conducting polymer film and biodegradable polymer microspheres. The 
interdigitated structure provided flexible drug delivery combination both for mono drug 
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delivery and dual drug delivery systems. The electrochemical impedance spectroscopy (EIS) 
and cyclic voltammetry (CV) results showed the excellent electrochemical properties of the 
3D electrodes. Conducting polymer coated electrodes demonstrated sustained near-linear 
release. The release amount of drug could be controlled by altering the stimuli potential. 
Assembling of two conducting polymer coated interdigitated electrodes significantly 
increased the capacity of drug loading. The biodegradable polymer microspheres coated 3D 
electrodes were also fabricated. By the assembling of microspheres coated electrode with the 
conducting polymer coated electrode, interdigitated dual drug delivery systems were 
developed. 
In summary, a series of biodegradable microcapsules and 3D conducting polymer drug 
delivery systems have been successfully developed in this thesis. All delivery systems 
showed biocompatibility, controllable shape, size, and drug release properties. These novel 
drug delivery systems demonstrate great potential application in the local treatment of central 
nervous system (CNS) disorders such as epilepsy. 
 
7.2 Future work 
 
7.2.1 Electrojetting biodegradable microcapsules 
Electrojetting has been a facile and simple technique for fabricating many kinds of 
microcapsules including micro-particles and microfibres [1-3]. These microcapsules 
demonstrated varied drug release profiles depending on their shape and size. The release 
periods are from several days to several months. However, further increasing the release time 
is still a huge challenge [4-6].  
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The drug release time already has been extended to several months by using the core-shell 
electrojetting technique. From the perspective of clinical applications, the longer release with 
even kinetics over the duration of the implant would be best. In order to further prolong the 
drug release duration, one promising method is to increase the shell/core ratio of the 
microcapsules [5]. For the microcapsules, the drug release rate decreases with increasing size 
of the microcapsules, as a result of increased diffusion distance.   
Another approach is to add a more hydrophobic component as drug carrier [7]. The 
hydrophobic component would prevent water penetration into the microcapsules. It will also 
decrease the degradation of the polymer carrier leading to reduction of drug diffusion. 
 
Two administrations would be applied to the delivery of electrojetting microparticles and 
microfibres to a patient. Because the granular polymeric delivery systems could be 
distributed in an injection solution, the microcapsules including microflakes, flattened 
microspheres, and microspheres are suitable for injected administration. However, for the 
fibrous polymeric delivery systems, which are gathered as fibre matrix,  administration  by 
implanting should be considered. 
 
For the electrospun microfibres and electrosprayed microspheres combined structure, it 
would be worth undertaking more detailed investigations incorporating modelling based on 
this new structure using a single drug.   
 
Apart from drug delivery applications, electrojetting microparticles and microfibres could be 
used in other biological areas such as cell culture and tissue engineering [6, 8]. Some 
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biomacromolecules e.g. protein, DNA, and growth factor could be incorporated into the 
biodegradable microcapsules for these related biomedical applications. 
 
7.2.2 Electropolymerization of conducting polymer 
3D printing is a novel technology for fabrication of complex, personalized products from 
digital designs [9-11]. Since a 3D printed drug had been approved by the FDA recently, 3D 
printing has attracted increasing interest in pharmaceutical fabrication [12]. In this study, 3D 
printed interdigitated electrodes were used as drug delivery systems. This technique also can 
be used to fabricate many other micro-structures. These structures can be designed to fulfil 
clinical requirements. Furthermore, the surface of the printed electrodes also can be modified 
by using conducting polymers and biodegradable polymers. 
Carbon nanomaterials, such as carbon nanotube, graphene, and graphene oxide have received 
tremendous attention in controlled drug delivery applications recently due to their large 
surface area and sp
2
 carbon lattice [13-18]. Graphene oxide is composed of a honeycomb 
carbon lattice structure with hydroxyl, carboxyl, and epoxide functional groups. The aromatic 
drug compounds enable π-π interactions with graphene oxide by localized π-electrons [19]. 





Figure 7.1 SEM images of PPy/graphene oxide/fosphenytoin coated on the surface of 3D 
printed electrode. 
Preliminary studies showed that the graphene oxide sheets could be incorporated into 
conducting polymer (PPy) film (Figure 7.1). The conducting polymer and graphene oxide 
could be co-deposited on the surface of the 3D printed microstructures. The as-fabricated 
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